#aadth ,,congress #b;d ,session ,s4 #ebd ,,an ,,act ,to authorize the ,attorney ,general to award grants to address the national epidemics of prescription opioid abuse and heroin use4 #a4 ,short title2 table of contents 7a7 ,short title ,this ,act may be cited as the ,comprehensive ,addiction and ,recovery ,act of #bjaf4 7b7 ,table of contents ,the table of contents for this ,act is as follows3 ,sec4 #a4 ,short title2 table of contents4,sec4 #b4 ,findings4,sec4 #c4 ,definitions4,,title ,i--,prevention and education,sec4 #aja4 ,development of best practices for the prescribing of prescription opioids4,sec4 #ajb4 ,awareness campaigns4,sec4 #ajc4 ,community-based coalition enhancement grants to address local drug crises4,,title ,,ii--,law enforcement and treatment,sec4 #bja4 ,treatment alternative to incarceration programs4,sec4 #bjb4 ,first responder training for the use of drugs and devices that rapidly reverse the effects of opioids4,sec4 #bjc4 ,prescription drug take back expansion4,sec4 #bjd4 ,heroin and methamphetamine task forces4,,title ,,iii--,treatment and recovery,sec4 #cja4 ,evidence-based prescription opioid and heroin treatment and interventions demonstration4,sec4 #cjb4 ,criminal justice medication assisted treatment and interventions demonstration4,sec4 #cjc4 ,national youth recovery initiative4,sec4 #cjd4 ,building communities of recovery4,,title ,,iv--,addressing collateral consequences,sec4 #dja4 ,correctional education demonstration grant program4,sec4 #djb4 ,national ,task ,force on ,recovery and ,collateral ,consequences4,,title ,v--,addiction and treatment services for women1 families1 and veterans,sec4 #eja4 ,improving treatment for pregnant and postpartum women4,sec4 #ejb4 ,report on grants for family-based substance abuse treatment4,sec4 #ejc4 ,veterans' treatment courts4,,title ,,vi--,incentivizing ,state comprehensive initiatives to address prescription opioid and heroin abuse,sec4 #fja4 ,state demonstration grants for comprehensive opioid abuse response4,,title ,,vii--,miscellaneous,sec4 #gja4 ,,gao report on ,,imd exclusion4,sec4 #gjb4 ,funding4,sec4 #gjc4 ,conforming amendments4,sec4 #gjd4 ,grant accountability4,sec4 #gje4 ,programs to prevent prescription drug abuse under the ,medicare program4,,title ,,viii--,transnational ,drug ,trafficking ,act ,sec4 #hja4 ,short title4 ,sec4 #hjb4 ,possession1 manufacture or distribution for purposes of unlawful importations4 ,sec4 #hjc4 ,trafficking in counterfeit goods or services4 #b4 ,findings ,congress finds the following3 7#a7 ,the abuse of heroin and prescription opioid painkillers is having a devastating effect on public health and safety in communities across the ,united ,states4 ,according to the ,centers for ,disease ,control and ,prevention1 drug overdose deaths now surpass traffic accidents in the number of deaths caused by injury in the ,united ,states4 ,in #bjad1 an average of more than #abj people in the ,united ,states died from drug overdoses every day4 7#b7 ,according to the ,national ,institute on ,drug ,abuse 7commonly known as ,,nida71 the number of prescriptions for opioids increased from approximately #gf1jjj1jjj in #aiia to nearly #bjg1jjj1jjj in #bjac1 and the ,united ,states is the biggest consumer of opioids globally1 accounting for almost #ajj percent of the world total for hydrocodone and #ha percent for oxycodone4 7#c7 ,opioid pain relievers are the most widely misused or abused controlled prescription drugs 7commonly referred to as ,c,p,ds7 and are involved in most ,,cpd-related overdose incidents4 ,according to the ,drug ,abuse ,warning ,network 7commonly known as ,,dawn71 the estimated number of emergency department visits involving nonmedical use of prescription opiates or opioids increased by #aab percent between #bjjf and #bjaj1 from #hd1fga to #agi1ghg4 7#d7 ,the use of heroin in the ,united ,states has also spiked sharply in recent years4 ,according to the most recent ,national ,survey on ,drug ,use and ,health1 more than #ijj1jjj people in the ,united ,states reported using heroin in #bjad1 nearly a #ce percent increase from the previous year4 ,heroin overdose deaths more than tripled from #bjaj to #bjad4 7#e7 ,the supply of cheap heroin available in the ,united ,states has increased dramatically as well1 largely due to the activity of ,mexican drug trafficking organizations4 ,the ,drug ,enforcement ,administration 7commonly known as the ,,dea7 estimates that heroin seizures at the ,mexican border have more than doubled since #bjaj1 and heroin production in ,mexico increased #fb percent from #bjac to #bjad4 ,while only #h percent of ,state and local law enforcement officials across the ,united ,states identified heroin as the greatest drug threat in their area in #bjjh1 that number rose to #ch percent in #bjae4 7#f7 ,law enforcement officials and treatment experts throughout the country report that many people who have misused prescription opioids have turned to heroin as a cheaper or more easily obtained alternative to prescription opioids4 7#g7 ,according to a report by the ,national ,association of ,state ,alcohol and ,drug ,abuse ,directors 7commonly referred to as ,,nasadad71 #cg ,states reported an increase in admissions to treatment for heroin use during the past #b years1 while admissions to treatment for prescription opiates increased #ejj percent from #bjjj to #bjab4 7#h7 ,research indicates that combating the opioid crisis1 including abuse of prescription painkillers and1 increasingly1 heroin1 requires a multipronged approach that involves prevention1 education1 monitoring1 law enforcement initiatives1 reducing drug diversion and the supply of illicit drugs1 expanding delivery of existing treatments 7including medication assisted treatments71 expanding access to overdose medications and interventions1 and the development of new medications for pain that can augment the existing treatment arsenal4 7#i7 ,substance use disorders are a treatable disease4 ,discoveries in the science of addiction have led to advances in the treatment of substance use disorders that help people stop abusing drugs and prescription medications and resume their productive lives4 7#aj7 ,according to the ,national ,survey on ,drug ,use and ,health1 approximately #bb1gjj1jjj people in the ,united ,states needed substance use disorder treatment in #bjac1 but only #b1ejj1jjj people received it4 ,furthermore1 current treatment services are not adequate to meet demand4 ,according to a report commissioned by the ,substance ,abuse and ,mental ,health ,services ,administration 7commonly known as ,,samhsa71 there are approximately #cb providers for every #a1jjj individuals needing substance use disorder treatment4 ,in some ,states1 the ratio is much lower4 7#aa7 ,the overall cost of drug abuse1 from health care- and criminal justice-related costs to lost productivity1 is steep1 totaling more than #gjj1jjj1jjj1jjj a year1 according to ,,nida4 ,effective substance abuse prevention can yield major economic dividends4 7#ab7 ,according to ,,nida1 when schools and communities properly implement science-validated substance abuse prevention programs1 abuse of alcohol1 tobacco1 and illicit drugs is reduced4 ,such programs help teachers1 parents1 and healthcare professionals shape the perceptions of youths about the risks of drug abuse4 7#ac7 ,diverting certain individuals with substance use disorders from criminal justice systems into community-based treatment can save billions of dollars and prevent sizeable numbers of crimes1 arrests1 and re-incarcerations over the course of those individuals' lives4 7#ad7 ,according to the ,,dea1 more than #b1gjj tons of expired1 unwanted prescription medications have been collected since the enactment of the ,secure and ,responsible ,drug ,disposal ,act of #bjaj 7,public ,law #aaa-bgc2 #abd ,stat4 #bheh74 7#ae7 ,faith-based1 holistic1 or drug-free models can provide a critical path to successful recovery for a number of people in the ,united ,states4 ,the #bjae membership survey conducted by ,alcoholics ,anonymous 7commonly known as ,,aa7 found that #gc percent of ,,aa members were sober longer than #a year and attended #b4e meetings per week4 7#af7 ,research shows that combining treatment medications with behavioral therapy is an effective way to facilitate success for some patients4 ,treatment approaches must be tailored to address the drug abuse patterns and drug-related medical1 psychiatric1 and social problems of each individual4 ,different types of medications may be useful at different stages of treatment or recovery to help a patient stop using drugs1 stay in treatment1 and avoid relapse4 ,patients have a range of options regarding their path to recovery and many have also successfully addressed drug abuse through the use of faith-based1 holistic1 or drug-free models4 7#ag7 ,individuals with mental illness1 especially severe mental illness1 are at considerably higher risk for substance abuse than the general population1 and the presence of a mental illness complicates recovery from substance abuse4 7#ah7 ,rural communities are especially susceptible to heroin and opioid abuse4 ,individuals in rural counties have higher rates of drug poisoning deaths1 including deaths from opioids4 ,according to the ,american ,journal of ,public ,health1 ,opioid poisonings in nonmetropolitan counties have increased at a rate greater than threefold the increase in metropolitan counties4 ,according to a ,february #ai1 #bjaf1 report from the ,maine ,rural ,health ,research ,center1 ,multiple studies document a higher prevalence of abuse among specific vulnerable rural populations1 particularly among youth1 women who are pregnant or experiencing partner violence1 and persons with co-occurring disorders4 #c4 ,definitions ,in this ,act-- 7#a7 the term first responder includes a firefighter1 law enforcement officer1 paramedic1 emergency medical technician1 or other individual 7including an employee of a legally organized and recognized volunteer organization1 whether compensated or not71 who1 in the course of professional duties1 responds to fire1 medical1 hazardous material1 or other similar emergencies2 7#b7 the term medication assisted treatment means the use1 for problems relating to heroin and other opioids1 of medications approved by the ,food and ,drug ,administration in combination with counseling and behavioral therapies2 7#c7 the term opioid means any drug having an addiction-forming or addiction-sustaining liability similar to morphine or being capable of conversion into a drug having such addiction-forming or addiction-sustaining liability2 and 7#d7 the term ,state means any ,state of the ,united ,states1 the ,district of ,columbia1 the ,commonwealth of ,puerto ,rico1 and any territory or possession of the ,united ,states4 ,i ,prevention and education #aja4 ,development of best practices for the prescribing of prescription opioids 7a7 ,definitions ,in this section-- 7#a7 the term ,secretary means the ,secretary of ,health and ,human ,services2 and 7#b7 the term task force means the ,pain ,management ,best ,practices ,interagency ,task ,force convened under subsection 7b74 7b7 ,interagency ,task ,force ,not later than ,december #ad1 #bjah1 the ,secretary1 in cooperation with the ,secretary of ,veterans ,affairs1 the ,secretary of ,defense1 and the ,administrator of the ,drug ,enforcement ,administration1 shall convene a ,pain ,management ,best ,practices ,interagency ,task ,force to review1 modify1 and update1 as appropriate1 best practices for pain management 7including chronic and acute pain7 and prescribing pain medication4 7c7 ,membership ,the task force shall be comprised of-- 7#a7 representatives of-- 7,a7 the ,department of ,health and ,human ,services2 7,b7 the ,department of ,veterans ,affairs2 7,c7 the ,food and ,drug ,administration2 7,d7 the ,department of ,defense2 7,e7 the ,drug ,enforcement ,administration2 7,f7 the ,centers for ,disease ,control and ,prevention2 7,g7 the ,national ,academy of ,medicine2 7,h7 the ,national ,institutes of ,health2 7,i7 the ,office of ,national ,drug ,control ,policy2 and 7,j7 the ,office of ,rural ,health ,policy of the ,department of ,health and ,human ,services2 7#b7 physicians1 dentists1 and nonphysician prescribers2 7#c7 pharmacists2 7#d7 experts in the fields of pain research and addiction research2 7#e7 representatives of-- 7,a7 pain management professional organizations2 7,b7 the mental health treatment community2 7,c7 the addiction treatment community2 7,d7 pain advocacy groups2 and 7,e7 groups with expertise around overdose reversal2 and 7#f7 other stakeholders1 as the ,secretary determines appropriate4 7d7 ,duties ,the task force shall-- 7#a7 not later than #ahj days after the date on which the task force is convened under subsection 7b71 review1 modify1 and update1 as appropriate1 best practices for pain management 7including chronic and acute pain7 and prescribing pain medication1 taking into consideration-- 7,a7 existing pain management research2 7,b7 recommendations from relevant conferences and existing relevant evidence-based guidelines2 7,c7 ongoing efforts at the ,state and local levels and by medical professional organizations to develop improved pain management strategies1 including consideration of alternatives to opioids to reduce opioid monotherapy in appropriate cases2 7,d7 the management of high-risk populations1 other than populations who suffer pain1 who-- 7i7 may use or be prescribed benzodiazepines1 alcohol1 and diverted opioids2 or 7ii7 receive opioids in the course of medical care2 and 7,e7 the ,proposed #bjaf ,guideline for ,prescribing ,opioids for ,chronic ,pain issued by the ,centers for ,disease ,control and ,prevention 7#hj ,fed4 ,reg4 #ggcea 7,december #ad1 #bjae77 and any final guidelines issued by the ,centers for ,disease ,control and ,prevention2 7#b7 solicit and take into consideration public comment on the practices developed under paragraph 7#a71 amending such best practices if appropriate2 and 7#c7 develop a strategy for disseminating information about the best practices to stakeholders1 as appropriate4 7e7 ,limitation ,the task force shall not have rulemaking authority4 7f7 ,report ,not later than #bgj days after the date on which the task force is convened under subsection 7b71 the task force shall submit to ,congress a report that includes-- 7#a7 the strategy for disseminating best practices for pain management 7including chronic and acute pain7 and prescribing pain medication1 as reviewed1 modified1 or updated under subsection 7d72 and 7#b7 recommendations for effectively applying the best practices described in paragraph 7#a7 to improve prescribing practices at medical facilities1 including medical facilities of the ,veterans ,health ,administration4 #ajb4 ,awareness campaigns 7a7 ,in general ,the ,secretary of ,health and ,human ,services1 in coordination with the ,attorney ,general1 shall advance the education and awareness of the public1 providers1 patients1 consumers1 and other appropriate entities regarding the risk of abuse of prescription opioid drugs if such products are not taken as prescribed1 including opioid and methadone abuse4 ,such education and awareness campaigns shall include information on the dangers of opioid abuse1 how to prevent opioid abuse including through safe disposal of prescription medications and other safety precautions1 and detection of early warning signs of addiction4 7b7 ,drug-,free ,media ,campaign 7#a7 ,in general ,the ,office of ,national ,drug ,control ,policy1 in coordination with the ,secretary of ,health and ,human ,services and the ,attorney ,general1 shall establish a national drug awareness campaign4 7#b7 ,requirements ,the national drug awareness campaign required under paragraph 7#a7 shall-- 7,a7 take into account the association between prescription opioid abuse and heroin use2 7,b7 emphasize the similarities between heroin and prescription opioids and the effects of heroin and prescription opioids on the human body2 and 7,c7 bring greater public awareness to the dangerous effects of fentanyl when mixed with heroin or abused in a similar manner4 #ajc4 ,community-based coalition enhancement grants to address local drug crises ,part ,,ii of title ,i of the ,omnibus ,crime ,control and ,safe ,streets ,act of #aifh 7#db ,u4,s4,c4 #cgig;cc et seq47 is amended by striking section #biig and inserting the following3 #biig4 ,community-based coalition enhancement grants to address local drug crises 7a7 ,definitions ,in this section-- 7#a7 the term ,drug-,free ,communities ,act of #aiig means chapter #b of the ,national ,narcotics ,leadership ,act of #aihh 7#ba ,u4,s4,c4 #aeba et seq472 7#b7 the term eligible entity means an organization that-- 7,a7 on or before the date of submitting an application for a grant under this section1 receives or has received a grant under the ,drug-,free ,communities ,act of #aiig2 and 7,b7 has documented1 using local data1 rates of abuse of opioids or methamphetamines at levels that are-- 7i7 significantly higher than the national average as determined by the ,secretary 7including appropriate consideration of the results of the ,monitoring the ,future ,survey published by the ,national ,institute on ,drug ,abuse and the ,national ,survey on ,drug ,use and ,health published by the ,substance ,abuse and ,mental ,health ,services ,administration72 or 7ii7 higher than the national average1 as determined by the ,secretary 7including appropriate consideration of the results of the surveys described in clause 7i771 over a sustained period of time2 7#c7 the term local drug crisis means1 with respect to the area served by an eligible entity-- 7,a7 a sudden increase in the abuse of opioids or methamphetamines1 as documented by local data2 7,b7 the abuse of prescription medications1 specifically opioids or methamphetamines1 that is significantly higher than the national average1 over a sustained period of time1 as documented by local data2 or 7,c7 a sudden increase in opioid-related deaths1 as documented by local data2 7#d7 the term opioid means any drug having an addiction-forming or addiction-sustaining liability similar to morphine or being capable of conversion into a drug having such addiction-forming or addiction-sustaining liability2 and 7#e7 the term ,secretary means the ,secretary of ,health and ,human ,services4 7b7 ,program authorized ,the ,secretary1 in coordination with the ,director of the ,office of ,national ,drug ,control ,policy1 may make grants to eligible entities to implement comprehensive community-wide strategies that address local drug crises within the area served by the eligible entity4 7c7 ,application 7#a7 ,in general ,an eligible entity seeking a grant under this section shall submit an application to the ,secretary at such time1 in such manner1 and accompanied by such information as the ,secretary may require4 7#b7 ,criteria ,as part of an application for a grant under this section1 the ,secretary shall require an eligible entity to submit a detailed1 comprehensive1 multisector plan for addressing the local drug crisis within the area served by the eligible entity4 7d7 ,use of funds ,an eligible entity shall use a grant received under this section-- 7#a7 for programs designed to implement comprehensive community-wide prevention strategies to address the local drug crisis in the area served by the eligible entity1 in accordance with the plan submitted under subsection 7c77#b72 and 7#b7 to obtain specialized training and technical assistance from the organization funded under section #d of ,public ,law #ajg-hb 7#ba ,u4,s4,c4 #aeba note74 7e7 ,supplement not supplant ,an eligible entity shall use ,federal funds received under this section only to supplement the funds that would1 in the absence of those ,federal funds1 be made available from other ,federal and non-,federal sources for the activities described in this section1 and not to supplant those funds4 7f7 ,evaluation ,a grant under this section shall be subject to the same evaluation requirements and procedures as the evaluation requirements and procedures imposed on the recipient of a grant under the ,drug-,free ,communities ,act of #aiig1 and may also include an evaluation of the effectiveness at reducing abuse of opioids1 methadone1 or methamphetamines4 7g7 ,limitation on administrative expenses ,not more than #h percent of the amounts made available to carry out this section for a fiscal year may be used by the ,secretary to pay for administrative expenses4 4 ,,ii ,law enforcement and treatment #bja4 ,treatment alternative to incarceration programs 7a7 ,definitions ,in this section3 7#a7 ,eligible entity ,the term eligible entity means a ,state1 unit of local government1 ,indian tribe1 or nonprofit organization4 7#b7 ,eligible participant ,the term eligible participant means an individual who-- 7,a7 comes into contact with the juvenile justice system or criminal justice system or is arrested or charged with an offense that is not-- 7i7 a crime of violence1 as defined under applicable ,state law or section #caef of title #ah1 ,united ,states ,code2 or 7ii7 a serious drug offense1 as defined under section #ibd7;e77#b77;,a7 of title #ah1 ,united ,states ,code2 7,b7 has been screened by a qualified mental health professional and determined to suffer from a substance use disorder1 or co-occurring mental illness and substance use disorder1 that there is a reasonable basis to believe is related to the commission of the offense2 and 7,c7 has been1 after consideration of any potential risk of violence to any person in the program or the public if the individual were selected to participate in the program1 unanimously approved for participation in a program funded under this section by1 as applicable depending on the stage of the criminal justice process-- 7i7 the relevant law enforcement agency2 7ii7 the prosecuting attorney2 7iii7 the defense attorney2 7iv7 the pretrial1 probation1 or correctional officer2 7v7 the judge2 and 7vi7 a representative from the relevant mental health or substance abuse agency4 7b7 ,program authorized ,the ,secretary of ,health and ,human ,services1 in coordination with the ,attorney ,general1 may make grants to eligible entities to-- 7#a7 develop1 implement1 or expand a treatment alternative to incarceration program for eligible participants1 including-- 7,a7 pre-booking1 including pre-arrest1 treatment alternative to incarceration programs1 including-- 7i7 law enforcement training on substance use disorders and co-occurring mental illness and substance use disorders2 7ii7 receiving centers as alternatives to incarceration of eligible participants2 7iii7 specialized response units for calls related to substance use disorders and co-occurring mental illness and substance use disorders2 and 7iv7 other pre-arrest or pre-booking treatment alternative to incarceration models2 and 7,b7 post-booking treatment alternative to incarceration programs1 including-- 7i7 specialized clinical case management2 7ii7 pretrial services related to substance use disorders and co-occurring mental illness and substance use disorders2 7iii7 prosecutor and defender based programs2 7iv7 specialized probation2 7v7 programs utilizing the ,american ,society of ,addiction ,medicine patient placement criteria2 7vi7 treatment and rehabilitation programs and recovery support services2 and 7vii7 drug courts1 ,,dwi courts1 and veterans treatment courts2 and 7#b7 facilitate or enhance planning and collaboration between ,state criminal justice systems and ,state substance abuse systems in order to more efficiently and effectively carry out programs described in paragraph 7#a7 that address problems related to the use of heroin and misuse of prescription drugs among eligible participants4 7c7 ,application 7#a7 ,in general ,an eligible entity seeking a grant under this section shall submit an application to the ,secretary of ,health and ,human ,services-- 7,a7 that meets the criteria under paragraph 7#b72 and 7,b7 at such time1 in such manner1 and accompanied by such information as the ,secretary of ,health and ,human ,services may require4 7#b7 ,criteria ,an eligible entity1 in submitting an application under paragraph 7#a71 shall-- 7,a7 provide extensive evidence of collaboration with ,state and local government agencies overseeing health1 community corrections1 courts1 prosecution1 substance abuse1 mental health1 victims services1 and employment services1 and with local law enforcement agencies2 7,b7 demonstrate consultation with the ,single ,state ,authority for ,substance ,abuse 7as defined in section #bja7;e7 of the ,second ,chance ,act of #bjjg 7#db ,u4,s4,c4 #ageba7;e7772 7,c7 demonstrate consultation with the ,single ,state criminal justice planning agency2 7,d7 demonstrate that evidence-based treatment practices1 including if applicable the use of medication assisted treatment1 will be utilized2 and 7,e7 demonstrate that evidenced-based screening and assessment tools will be utilized to place participants in the treatment alternative to incarceration program4 7d7 ,requirements ,each eligible entity awarded a grant for a treatment alternative to incarceration program under this section shall-- 7#a7 determine the terms and conditions of participation in the program by eligible participants1 taking into consideration the collateral consequences of an arrest1 prosecution1 or criminal conviction2 7#b7 ensure that each substance abuse and mental health treatment component is licensed and qualified by the relevant jurisdiction2 7#c7 for programs described in subsection 7b77#b71 organize an enforcement unit comprised of appropriately trained law enforcement professionals under the supervision of the ,state1 tribal1 or local criminal justice agency involved1 the duties of which shall include-- 7,a7 the verification of addresses and other contacts of each eligible participant who participates or desires to participate in the program2 and 7,b7 if necessary1 the location1 apprehension1 arrest1 and return to court of an eligible participant in the program who has absconded from the facility of a treatment provider or has otherwise violated the terms and conditions of the program1 consistent with ,federal and ,state confidentiality requirements2 7#d7 notify the relevant criminal justice entity if any eligible participant in the program absconds from the facility of the treatment provider or otherwise violates the terms and conditions of the program1 consistent with ,federal and ,state confidentiality requirements2 7#e7 submit periodic reports on the progress of treatment or other measured outcomes from participation in the program of each eligible participant in the program to the relevant ,state1 tribal1 or local criminal justice agency2 7#f7 describe the evidence-based methodology and outcome measurements that will be used to evaluate the program1 and specifically explain how such measurements will provide valid measures of the impact of the program2 and 7#g7 describe how the program could be broadly replicated if demonstrated to be effective4 7e7 ,use of funds ,an eligible entity shall use a grant received under this section for expenses of a treatment alternative to incarceration program1 including-- 7#a7 salaries1 personnel costs1 equipment costs1 and other costs directly related to the operation of the program1 including the enforcement unit2 7#b7 payments for treatment providers that are approved by the relevant ,state or tribal jurisdiction and licensed1 if necessary1 to provide needed treatment to eligible participants in the program1 including medication assisted treatment1 aftercare supervision1 vocational training1 education1 and job placement2 7#c7 payments to public and nonprofit private entities that are approved by the ,state or tribal jurisdiction and licensed1 if necessary1 to provide alcohol and drug addiction treatment and mental health treatment to eligible participants in the program2 and 7#d7 salaries1 personnel costs1 and other costs related to strategic planning among ,state and local government agencies4 7f7 ,supplement not supplant ,an eligible entity shall use ,federal funds received under this section only to supplement the funds that would1 in the absence of those ,federal funds1 be made available from other ,federal and non-,federal sources for the activities described in this section1 and not to supplant those funds4 7g7 ,geographic distribution ,the ,secretary of ,health and ,human ,services shall ensure that1 to the extent practicable1 the geographical distribution of grants under this section is equitable and includes a grant to an eligible entity in-- 7#a7 each ,state2 7#b7 rural1 suburban1 and urban areas2 and 7#c7 tribal jurisdictions4 7h7 ,priority consideration with respect to ,states ,in awarding grants to ,states under this section1 the ,secretary of ,health and ,human ,services shall give priority to-- 7#a7 a ,state that submits a joint application from the substance abuse agencies and criminal justice agencies of the ,state that proposes to use grant funds to facilitate or enhance planning and collaboration between the agencies1 including coordination to better address the needs of incarcerated populations2 and 7#b7 a ,state that-- 7,a7 provides civil liability protection for first responders1 health professionals1 and family members who have received appropriate training in the administration of naloxone in administering naloxone to counteract opioid overdoses2 and 7,b7 submits to the ,secretary a certification by the attorney general of the ,state that the attorney general has-- 7i7 reviewed any applicable civil liability protection law to determine the applicability of the law with respect to first responders1 health care professionals1 family members1 and other individuals who-- 7,i7 have received appropriate training in the administration of naloxone2 and 7,,ii7 may administer naloxone to individuals reasonably believed to be suffering from opioid overdose2 and 7ii7 concluded that the law described in subparagraph 7,a7 provides adequate civil liability protection applicable to such persons4 7i7 ,reports and evaluations 7#a7 ,in general ,each fiscal year1 each recipient of a grant under this section during that fiscal year shall submit to the ,secretary of ,health and ,human ,services a report on the outcomes of activities carried out using that grant in such form1 containing such information1 and on such dates as the ,secretary of ,health and ,human ,services shall specify4 7#b7 ,contents ,a report submitted under paragraph 7#a7 shall-- 7,a7 describe best practices for treatment alternatives2 and 7,b7 identify training requirements for law enforcement officers who participate in treatment alternative to incarceration programs4 7j7 ,funding ,during the #e-year period beginning on the date of enactment of this ,act1 the ,secretary of ,health and ,human ,services may carry out this section using not more than #e1jjj1jjj each fiscal year of amounts appropriated to the ,substance ,abuse and ,mental ,health ,services ,administration for ,criminal ,justice ,activities4 ,no additional funds are authorized to be appropriated to carry out this section4 #bjb4 ,first responder training for the use of drugs and devices that rapidly reverse the effects of opioids ,part ,,ii of title ,i of the ,omnibus ,crime ,control and ,safe ,streets ,act of #aifh 7#db ,u4,s4,c4 #cgig;cc et seq471 as amended by section #ajc1 is amended by adding at the end the following3 #biih4 ,first responder training for the use of drugs and devices that rapidly reverse the effects of opioids 7a7 ,definition ,in this section-- 7#a7 the terms drug and device have the meanings given those terms in section #bja of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cba72 7#b7 the term eligible entity means a ,state1 a unit of local government1 or an ,indian tribal government2 7#c7 the term first responder includes a firefighter1 law enforcement officer1 paramedic1 emergency medical technician1 or other individual 7including an employee of a legally organized and recognized volunteer organization1 whether compensated or not71 who1 in the course of professional duties1 responds to fire1 medical1 hazardous material1 or other similar emergencies2 7#d7 the term opioid means any drug having an addiction-forming or addiction-sustaining liability similar to morphine or being capable of conversion into a drug having such addiction-forming or addiction-sustaining liability2 and 7#e7 the term ,secretary means the ,secretary of ,health and ,human ,services4 7b7 ,program authorized ,the ,secretary1 in coordination with the ,attorney ,general1 may make grants to eligible entities to allow appropriately trained first responders to administer an opioid overdose reversal drug to an individual who has-- 7#a7 experienced a prescription opioid or heroin overdose2 or 7#b7 been determined to have likely experienced a prescription opioid or heroin overdose4 7c7 ,application 7#a7 ,in general ,an eligible entity seeking a grant under this section shall submit an application to the ,secretary-- 7,a7 that meets the criteria under paragraph 7#b72 and 7,b7 at such time1 in such manner1 and accompanied by such information as the ,secretary may require4 7#b7 ,criteria ,an eligible entity1 in submitting an application under paragraph 7#a71 shall-- 7,a7 describe the evidence-based methodology and outcome measurements that will be used to evaluate the program funded with a grant under this section1 and specifically explain how such measurements will provide valid measures of the impact of the program2 7,b7 describe how the program could be broadly replicated if demonstrated to be effective2 7,c7 identify the governmental and community agencies that the program will coordinate2 and 7,d7 describe how law enforcement agencies will coordinate with their corresponding ,state substance abuse and mental health agencies to identify protocols and resources that are available to overdose victims and families1 including information on treatment and recovery resources4 7d7 ,use of funds ,an eligible entity shall use a grant received under this section to-- 7#a7 make such opioid overdose reversal drugs or devices that are approved by the ,food and ,drug ,administration1 such as naloxone1 available to be carried and administered by first responders2 7#b7 train and provide resources for first responders on carrying an opioid overdose reversal drug or device approved by the ,food and ,drug ,administration1 such as naloxone1 and administering the drug or device to an individual who has experienced1 or has been determined to have likely experienced1 a prescription opioid or heroin overdose2 and 7#c7 establish processes1 protocols1 and mechanisms for referral to appropriate treatment1 which may include an outreach coordinator or team to connect individuals receiving opioid overdose reversal drugs to follow-up services4 7e7 ,technical assistance grants ,the ,secretary shall make a grant for the purpose of providing technical assistance and training on the use of an opioid overdose reversal drug1 such as naloxone1 to respond to an individual who has experienced1 or has been determined to have likely experienced1 a prescription opioid or heroin overdose1 and mechanisms for referral to appropriate treatment for an eligible entity receiving a grant under this section4 7f7 ,evaluation ,the ,secretary shall conduct an evaluation of grants made under this section to determine-- 7#a7 the number of first responders equipped with naloxone1 or another opioid overdose reversal drug1 for the prevention of fatal opioid and heroin overdose2 7#b7 the number of opioid and heroin overdoses reversed by first responders receiving training and supplies of naloxone1 or another opioid overdose reversal drug1 through a grant received under this section2 7#c7 the number of calls for service related to opioid and heroin overdose2 7#d7 the extent to which overdose victims and families receive information about treatment services and available data describing treatment admissions2 and 7#e7 the research1 training1 and naloxone1 or another opioid overdose reversal drug1 supply needs of first responder agencies1 including those agencies that are not receiving grants under this section4 7g7 ,rural areas with limited access to emergency medical services ,in making grants under this section1 the ,secretary shall ensure that not less than #be percent of grant funds are awarded to eligible entities that are not located in metropolitan statistical areas1 as defined by the ,office of ,management and ,budget4 4 #bjc4 ,prescription drug take back expansion 7a7 ,definition of covered entity ,in this section1 the term covered entity means-- 7#a7 a ,state1 local1 or tribal law enforcement agency2 7#b7 a manufacturer1 distributor1 or reverse distributor of prescription medications2 7#c7 a retail pharmacy2 7#d7 a registered narcotic treatment program2 7#e7 a hospital or clinic with an onsite pharmacy2 7#f7 an eligible long-term care facility2 or 7#g7 any other entity authorized by the ,drug ,enforcement ,administration to dispose of prescription medications4 7b7 ,program authorized ,the ,attorney ,general1 in coordination with the ,administrator of the ,drug ,enforcement ,administration1 the ,secretary of ,health and ,human ,services1 and the ,director of the ,office of ,national ,drug ,control ,policy1 shall coordinate with covered entities in expanding or making available disposal sites for unwanted prescription medications4 #bjd4 ,heroin and methamphetamine task forces ,part ,,ii of title ,i of the ,omnibus ,crime ,control and ,safe ,streets ,act of #aifh 7#db ,u4,s4,c4 #cgig;cc et seq471 as amended by section #bjb1 is amended by adding at the end the following3 #biii4 ,heroin and methamphetamine task forces 7a7 ,definition of opioid ,in this section1 the term opioid means any drug having an addiction-forming or addiction-sustaining liability similar to morphine or being capable of conversion into a drug having such addiction-forming or addiction-sustaining liability4 7b7 ,authority ,the ,attorney ,general may make grants to ,state law enforcement agencies for investigative purposes-- 7#a7 to locate or investigate illicit activities through statewide collaboration1 including activities related to-- 7,a7 the distribution of heroin or fentanyl1 or the unlawful distribution of prescription opioids2 or 7,b7 unlawful heroin1 fentanyl1 and prescription opioid traffickers2 and 7#b7 to locate or investigate illicit activities1 including precursor diversion1 laboratories1 or methamphetamine traffickers4 4 ,,iii ,treatment and recovery #cja4 ,evidence-based prescription opioid and heroin treatment and interventions demonstration ,part ,,ii of title ,i of the ,omnibus ,crime ,control and ,safe ,streets ,act of #aifh 7#db ,u4,s4,c4 #cgig;cc et seq471 as amended by section #bjd1 is amended by adding at the end the following3 #biii;,a4 ,evidence-based prescription opioid and heroin treatment and interventions demonstration 7a7 ,definitions ,in this section-- 7#a7 the terms ,indian tribe and tribal organization have the meaning given those terms in section #d of the ,indian ,health ,care ,improvement ,act 7#be ,u4,s4,c4 #afjc772 7#b7 the term medication assisted treatment means the use1 for problems relating to heroin and other opioids1 of medications approved by the ,food and ,drug ,administration in combination with counseling and behavioral therapies2 7#c7 the term opioid means any drug having an addiction-forming or addiction-sustaining liability similar to morphine or being capable of conversion into a drug having such addiction-forming or addiction-sustaining liability2 7#d7 the term ,secretary means the ,secretary of ,health and ,human ,services2 and 7#e7 the term ,state substance abuse agency means the agency of a ,state responsible for the ,state prevention1 treatment1 and recovery system1 including management of the ,substance ,abuse ,prevention and ,treatment ,block ,grant under subpart ,,ii of part ,b of title ,,xix of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #cjjx-#ba et seq474 7b7 ,grants 7#a7 ,authority to make grants ,the ,secretary1 acting through the ,director of the ,center for ,substance ,abuse ,treatment of the ,substance ,abuse and ,mental ,health ,services ,administration1 and in coordination with the ,attorney ,general and other departments or agencies1 as appropriate1 may award grants to ,state substance abuse agencies1 units of local government1 nonprofit organizations1 and ,indian tribes or tribal organizations that have a high rate1 or have had a rapid increase1 in the use of heroin or other opioids1 in order to permit such entities to expand activities1 including an expansion in the availability of medication assisted treatment and other clinically appropriate services1 with respect to the treatment of addiction in the specific geographical areas of such entities where there is a high rate or rapid increase in the use of heroin or other opioids4 7#b7 ,nature of activities ,the grant funds awarded under paragraph 7#a7 shall be used for activities that are based on reliable scientific evidence of efficacy in the treatment of problems related to heroin or other opioids4 7c7 ,geographic distribution ,the ,secretary shall ensure that grants awarded under subsection 7b7 are distributed equitably among the various regions of the ,united ,states and among rural1 urban1 and suburban areas that are affected by the use of heroin or other opioids4 7d7 ,additional activities ,in administering grants under subsection 7b71 the ,secretary shall-- 7#a7 evaluate the activities supported by grants awarded under subsection 7b72 7#b7 disseminate information1 as appropriate1 derived from the evaluation as the ,secretary considers appropriate2 7#c7 provide ,states1 ,indian tribes and tribal organizations1 and providers with technical assistance in connection with the provision of treatment of problems related to heroin and other opioids2 and 7#d7 fund only those applications that specifically support recovery services as a critical component of the grant program4 4 #cjb4 ,criminal justice medication assisted treatment and interventions demonstration 7a7 ,definitions ,in this section-- 7#a7 the term criminal justice agency means a ,state1 local1 or tribal-- 7,a7 court2 7,b7 prison2 7,c7 jail2 or 7,d7 other agency that performs the administration of criminal justice1 including prosecution1 pretrial services1 and community supervision2 7#b7 the term eligible entity means a ,state1 unit of local government1 or ,indian tribe2 and 7#c7 the term ,secretary means the ,secretary of ,health and ,human ,services4 7b7 ,program authorized ,the ,secretary1 in coordination with the ,attorney ,general1 may make grants to eligible entities to implement medication assisted treatment programs through criminal justice agencies4 7c7 ,application 7#a7 ,in general ,an eligible entity seeking a grant under this section shall submit an application to the ,secretary-- 7,a7 that meets the criteria under paragraph 7#b72 and 7,b7 at such time1 in such manner1 and accompanied by such information as the ,secretary may require4 7#b7 ,criteria ,an eligible entity1 in submitting an application under paragraph 7#a71 shall-- 7,a7 certify that each medication assisted treatment program funded with a grant under this section has been developed in consultation with the ,single ,state ,authority for ,substance ,abuse 7as defined in section #bja7;e7 of the ,second ,chance ,act of #bjjg 7#db ,u4,s4,c4 #ageba7;e7772 and 7,b7 describe how data will be collected and analyzed to determine the effectiveness of the program described in subparagraph 7,a74 7d7 ,use of funds ,an eligible entity shall use a grant received under this section for expenses of-- 7#a7 a medication assisted treatment program1 including the expenses of prescribing medications recognized by the ,food and ,drug ,administration for opioid treatment in conjunction with psychological and behavioral therapy2 7#b7 training criminal justice agency personnel and treatment providers on medication assisted treatment2 7#c7 cross-training personnel providing behavioral health and health services1 administration of medicines1 and other administrative expenses1 including required reports2 and 7#d7 the provision of recovery coaches who are responsible for providing mentorship and transition plans to individuals reentering society following incarceration or alternatives to incarceration4 7e7 ,priority consideration with respect to ,states ,in awarding grants to ,states under this section1 the ,secretary shall give priority to a ,state that-- 7#a7 provides civil liability protection for first responders1 health professionals1 and family members who have received appropriate training in the administration of naloxone in administering naloxone to counteract opioid overdoses2 and 7#b7 submits to the ,secretary a certification by the attorney general of the ,state that the attorney general has-- 7,a7 reviewed any applicable civil liability protection law to determine the applicability of the law with respect to first responders1 health care professionals1 family members1 and other individuals who-- 7i7 have received appropriate training in the administration of naloxone2 and 7ii7 may administer naloxone to individuals reasonably believed to be suffering from opioid overdose2 and 7,b7 concluded that the law described in subparagraph 7,a7 provides adequate civil liability protection applicable to such persons4 7f7 ,technical assistance ,the ,secretary1 in coordination with the ,director of the ,national ,institute on ,drug ,abuse and the ,attorney ,general1 shall provide technical assistance and training for an eligible entity receiving a grant under this section4 7g7 ,reports 7#a7 ,in general ,an eligible entity receiving a grant under this section shall submit a report to the ,secretary on the outcomes of each grant received under this section for individuals receiving medication assisted treatment1 based on-- 7,a7 the recidivism of the individuals2 7,b7 the treatment outcomes of the individuals1 including maintaining abstinence from illegal1 unauthorized1 and unprescribed or undispensed opioids and heroin2 7,c7 a comparison of the cost of providing medication assisted treatment to the cost of incarceration or other participation in the criminal justice system2 7,d7 the housing status of the individuals2 and 7,e7 the employment status of the individuals4 7#b7 ,contents and timing ,each report described in paragraph 7#a7 shall be submitted annually in such form1 containing such information1 and on such dates as the ,secretary shall specify4 7h7 ,funding ,during the #e-year period beginning on the date of enactment of this ,act1 the ,secretary may carry out this section using not more than #e1jjj1jjj each fiscal year of amounts appropriated to the ,substance ,abuse and ,mental ,health ,services ,administration for ,criminal ,justice ,activities4 ,no additional funds are authorized to be appropriated to carry out this section4 #cjc4 ,national youth recovery initiative ,part ,,ii of title ,i of the ,omnibus ,crime ,control and ,safe ,streets ,act of #aifh 7#db ,u4,s4,c4 #cgig;cc et seq471 as amended by section #cja1 is amended by adding at the end the following3 #biii;,b4 ,national youth recovery initiative 7a7 ,definitions ,in this section3 7#a7 ,eligible entity ,the term eligible entity means-- 7,a7 a high school that has been accredited as a recovery high school by the ,association of ,recovery ,schools2 7,b7 an accredited high school that is seeking to establish or expand recovery support services2 7,c7 an institution of higher education2 7,d7 a recovery program at a nonprofit collegiate institution2 or 7,e7 a nonprofit organization4 7#b7 ,institution of higher education ,the term institution of higher education has the meaning given the term in section #aja of the ,higher ,education ,act of #aife 7#bj ,u4,s4,c4 #ajja74 7#c7 ,recovery program ,the term recovery program-- 7,a7 means a program to help individuals who are recovering from substance use disorders to initiate1 stabilize1 and maintain healthy and productive lives in the community2 and 7,b7 includes peer-to-peer support and communal activities to build recovery skills and supportive social networks4 7b7 ,grants authorized ,the ,secretary of ,health and ,human ,services1 in coordination with the ,secretary of ,education1 may award grants to eligible entities to enable the entities to-- 7#a7 provide substance use disorder recovery support services to young people in high school and enrolled in institutions of higher education2 7#b7 help build communities of support for young people in recovery through a spectrum of activities such as counseling and health- and wellness-oriented social activities2 and 7#c7 encourage initiatives designed to help young people achieve and sustain recovery from substance use disorders4 7c7 ,use of funds ,grants awarded under subsection 7b7 may be used for activities to develop1 support1 and maintain youth recovery support services1 including-- 7#a7 the development and maintenance of a dedicated physical space for recovery programs2 7#b7 dedicated staff for the provision of recovery programs2 7#c7 health- and wellness-oriented social activities and community engagement2 7#d7 establishment of recovery high schools2 7#e7 coordination of recovery programs with-- 7,a7 substance use disorder treatment programs and systems2 7,b7 providers of mental health services2 7,c7 primary care providers and physicians2 7,d7 the criminal justice system1 including the juvenile justice system2 7,e7 employers2 7,f7 housing services2 7,g7 child welfare services2 7,h7 high schools and institutions of higher education2 and 7,i7 other programs or services related to the welfare of an individual in recovery from a substance use disorder2 7#f7 the development of peer-to-peer support programs or services2 and 7#g7 additional activities that help youths and young adults to achieve recovery from substance use disorders4 4 #cjd4 ,building communities of recovery ,part ,,ii of title ,i of the ,omnibus ,crime ,control and ,safe ,streets ,act of #aifh 7#db ,u4,s4,c4 #cgig;cc et seq471 as amended by section #cjc1 is amended by adding at the end the following3 #biii;,c4 ,building communities of recovery 7a7 ,definition ,in this section1 the term recovery community organization means an independent nonprofit organization that-- 7#a7 mobilizes resources within and outside of the recovery community to increase the prevalence and quality of long-term recovery from substance use disorders2 and 7#b7 is wholly or principally governed by people in recovery for substance use disorders who reflect the community served4 7b7 ,grants authorized ,the ,secretary of ,health and ,human ,services may award grants to recovery community organizations to enable such organizations to develop1 expand1 and enhance recovery services4 7c7 ,federal share ,the ,federal share of the costs of a program funded by a grant under this section may not exceed #ej percent4 7d7 ,use of funds ,grants awarded under subsection 7b7-- 7#a7 shall be used to develop1 expand1 and enhance community and statewide recovery support services2 and 7#b7 may be used to-- 7,a7 advocate for individuals in recovery from substance use disorders2 7,b7 build connections between recovery networks1 between recovery community organizations1 and with other recovery support services1 including-- 7i7 substance use disorder treatment programs and systems2 7ii7 providers of mental health services2 7iii7 primary care providers and physicians2 7iv7 the criminal justice system2 7v7 employers2 7vi7 housing services2 7vii7 child welfare agencies2 and 7viii7 other recovery support services that facilitate recovery from substance use disorders2 7,c7 reduce the stigma associated with substance use disorders2 7,d7 conduct public education and outreach on issues relating to substance use disorders and recovery1 including-- 7i7 how to identify the signs of addiction2 7ii7 the resources that are available to individuals struggling with addiction and families who have a family member struggling with or being treated for addiction1 including programs that mentor and provide support services to children2 7iii7 the resources that are available to help support individuals in recovery2 and 7iv7 information on the medical consequences of substance use disorders1 including neonatal abstinence syndrome and potential infection with human immunodeficiency virus and viral hepatitis2 and 7,e7 carry out other activities that strengthen the network of community support for individuals in recovery4 4 ,,iv ,addressing collateral consequences #dja4 ,correctional education demonstration grant program ,part ,,ii of title ,i of the ,omnibus ,crime ,control and ,safe ,streets ,act of #aifh 7#db ,u4,s4,c4 #cgig;cc et seq471 as amended by section #cjd1 is amended by adding at the end the following3 #biii;,d4 ,correctional education demonstration grant program 7a7 ,definition ,in this section1 the term eligible entity means a ,state1 unit of local government1 nonprofit organization1 or ,indian tribe4 7b7 ,grant program authorized ,the ,attorney ,general may make grants to eligible entities to design1 implement1 and expand educational programs for offenders in prisons1 jails1 and juvenile facilities1 including to pay for-- 7#a7 basic education1 secondary level academic education1 high school equivalency examination preparation1 career technical education1 and ,english language learner instruction at the basic1 secondary1 or post-secondary levels1 for adult and juvenile populations2 7#b7 screening and assessment of inmates to assess education level and needs1 occupational interest or aptitude1 risk level1 and other needs1 and case management services2 7#c7 hiring and training of instructors and aides1 reimbursement of non-corrections staff and experts1 reimbursement of stipends paid to inmate tutors or aides1 and the costs of training inmate tutors and aides2 7#d7 instructional supplies and equipment1 including occupational program supplies and equipment to the extent that the supplies and equipment are used for instructional purposes2 7#e7 partnerships and agreements with community colleges1 universities1 and career technology education program providers2 7#f7 certification programs providing recognized high school equivalency certificates and industry recognized credentials2 and 7#g7 technology solutions to-- 7,a7 meet the instructional1 assessment1 and information needs of correctional populations2 and 7,b7 facilitate the continued participation of incarcerated students in community-based education programs after the students are released from incarceration4 7c7 ,application ,an eligible entity seeking a grant under this section shall submit to the ,attorney ,general an application in such form and manner1 at such time1 and accompanied by such information as the ,attorney ,general specifies4 7d7 ,priority considerations ,in awarding grants under this section1 the ,attorney ,general shall give priority to applicants that-- 7#a7 assess the level of risk and need of inmates1 including by-- 7,a7 assessing the need for ,english language learner instruction2 7,b7 conducting educational assessments2 and 7,c7 assessing occupational interests and aptitudes2 7#b7 target educational services to assessed needs1 including academic and occupational at the basic1 secondary1 or post-secondary level2 7#c7 target career and technology education programs to-- 7,a7 areas of identified occupational demand2 and 7,b7 employment opportunities in the communities in which students are reasonably expected to reside post-release2 7#d7 include a range of appropriate educational opportunities at the basic1 secondary1 and post-secondary levels2 7#e7 include opportunities for students to attain industry recognized credentials2 7#f7 include partnership or articulation agreements linking institutional education programs with community sited programs provided by adult education program providers and accredited institutions of higher education1 community colleges1 and vocational training institutions2 and 7#g7 explicitly include career pathways models offering opportunities for incarcerated students to develop academic skills1 in-demand occupational skills and credentials1 occupational experience in institutional work programs or work release programs1 and linkages with employers in the community1 so that incarcerated students have opportunities to embark on careers with strong prospects for both post-release employment and advancement in a career ladder over time4 7e7 ,requirements ,an eligible entity seeking a grant under this section shall-- 7#a7 describe the evidence-based methodology and outcome measurements that will be used to evaluate each program funded with a grant under this section1 and specifically explain how such measurements will provide valid measures of the impact of the program2 and 7#b7 describe how each program described in paragraph 7#a7 could be broadly replicated if demonstrated to be effective4 7f7 ,control of ,internet access ,an entity that receives a grant under this section may restrict access to the ,internet by prisoners1 as appropriate and in accordance with ,federal and ,state law1 to ensure public safety4 4 #djb4 ,national ,task ,force on ,recovery and ,collateral ,consequences 7a7 ,definition ,in this section1 the term collateral consequence means a penalty1 disability1 or disadvantage imposed on an individual who is in recovery for a substance use disorder 7including by an administrative agency1 official1 or civil court 7 as a result of a ,federal or ,state conviction for a drug-related offense but not as part of the judgment of the court that imposes the conviction4 7b7 ,establishment 7#a7 ,in general ,not later than #cj days after the date of enactment of this ,act1 the ,attorney ,general shall establish a bipartisan task force to be known as the ,task ,force on ,recovery and ,collateral ,consequences 7in this section referred to as the ,task ,force74 7#b7 ,membership 7,a7 ,total number of members ,the ,task ,force shall include #aj members1 who shall be appointed by the ,attorney ,general in accordance with subparagraphs 7,b7 and 7,c74 7,b7 ,members of the task force ,the ,task ,force shall include-- 7i7 members who have national recognition and significant expertise in areas such as health care1 housing1 employment1 substance use disorders1 mental health1 law enforcement1 and law2 7ii7 not fewer than #b members-- 7,i7 who have personally experienced a substance abuse disorder or addiction and are in recovery2 and 7,,ii7 not fewer than #a of whom has benefitted from medication assisted treatment2 and 7iii7 to the extent practicable1 members who formerly served as elected officials at the ,state and ,federal levels4 7,c7 ,timing ,the ,attorney ,general shall appoint the members of the ,task ,force not later than #fj days after the date on which the ,task ,force is established under paragraph 7#a74 7#c7 ,chairperson ,the ,task ,force shall select a chairperson or co-chairpersons from among the members of the ,task ,force4 7c7 ,duties of the task force 7#a7 ,in general ,the ,task ,force shall-- 7,a7 identify collateral consequences for individuals with ,federal or ,state convictions for drug-related offenses who are in recovery for substance use disorder2 and 7,b7 examine any policy basis for the imposition of collateral consequences identified under subparagraph 7,a7 and the effect of the collateral consequences on individuals in recovery in resuming their personal and professional activities4 7#b7 ,recommendations ,not later than #ahj days after the date of the first meeting of the ,task ,force1 the ,task ,force shall develop recommendations1 as it considers appropriate1 for proposed legislative and regulatory changes related to the collateral consequences identified under paragraph 7#a74 7#c7 ,collection of information ,the ,task ,force shall hold hearings1 require the testimony and attendance of witnesses1 and secure information from any department or agency of the ,united ,states in performing the duties under paragraphs 7#a7 and 7#b74 7#d7 ,report 7,a7 ,submission to executive branch ,not later than #a year after the date of the first meeting of the ,task ,force1 the ,task ,force shall submit a report detailing the findings and recommendations of the ,task ,force to-- 7i7 the head of each relevant department or agency of the ,united ,states2 7ii7 the ,president2 and 7iii7 the ,vice ,president4 7,b7 ,submission to ,congress ,the individuals who receive the report under subparagraph 7,a7 shall submit to ,congress such legislative recommendations1 if any1 as those individuals consider appropriate based on the report4 ,v ,addiction and treatment services for women1 families1 and veterans #eja4 ,improving treatment for pregnant and postpartum women 7a7 ,in general ,section #ejh of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bij;bb-#a7 is amended-- 7#a7 in subsection 7a71 by inserting 7referred to in this section as the ,director7 after ,director of the ,center for ,substance ,abuse ,treatment2 and 7#b7 in subsection 7p71 in the first sentence-- 7,a7 by striking ,committee on ,labor and ,human ,resources and inserting ,committee on ,health1 ,education1 ,labor1 and ,pensions2 and 7,b7 by inserting 7other than subsection 7r77 after this section4 7b7 ,pilot program grants for ,state substance abuse agencies ,section #ejh of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bij;bb-#a7 is amended-- 7#a7 by striking subsection 7r72 and 7#b7 by inserting after subsection 7q7 the following3 7r7 ,pilot program for state substance abuse agencies 7#a7 ,in general ,the ,director shall carry out a pilot program under which the ,director makes competitive grants to ,state substance abuse agencies to-- 7,a7 enhance flexibility in the use of funds designed to support family-based services for pregnant and postpartum women with a primary diagnosis of a substance use disorder1 including opioid use disorders2 7,b7 help ,state substance abuse agencies address identified gaps in services furnished to such women along the continuum of care1 including services provided to women in non-residential based settings2 and 7,c7 promote a coordinated1 effective1 and efficient ,state system managed by ,state substance abuse agencies by encouraging new approaches and models of service delivery that are evidence-based1 including effective family-based programs for women involved with the criminal justice system4 7#b7 ,requirements ,in carrying out the pilot program under this subsection1 the ,director-- 7,a7 shall require ,state substance abuse agencies to submit to the ,director applications1 in such form and manner and containing such information as specified by the ,director1 to be eligible to receive a grant under the program2 7,b7 shall identify1 based on such submitted applications1 ,state substance abuse agencies that are eligible for such grants2 7,c7 shall require services proposed to be furnished through such a grant to support family-based treatment and other services for pregnant and postpartum women with a primary diagnosis of a substance use disorder1 including opioid use disorders2 7,d7 notwithstanding subsection 7a77#a71 shall not require that services furnished through such a grant be provided solely to women that reside in facilities2 and 7,e7 shall not require that grant recipients under the program make available all services described in subsection 7d74 7#c7 ,required services 7,a7 ,in general ,the ,director shall specify minimum services required to be made available to eligible women through a grant awarded under the pilot program under this subsection4 ,such minimum services-- 7i7 shall include the requirements described in subsection 7c72 7ii7 may include any of the services described in subsection 7d72 7iii7 may include other services1 as appropriate2 and 7iv7 shall be based on the recommendations submitted under subparagraph 7,b7 7,b7 ,stakeholder input ,the ,director shall convene and solicit recommendations from stakeholders1 including ,state substance abuse agencies1 health care providers1 persons in recovery from a substance use disorder1 and other appropriate individuals1 for the minimum services described in subparagraph 7,a74 7#d7 ,duration ,the pilot program under this subsection shall not exceed #e years4 7#e7 ,evaluation and report to ,congress 7,a7 ,in general ,out of amounts made available to the ,center for ,behavioral ,health ,statistics and ,quality1 the ,director of the ,center for ,behavioral ,health ,statistics and ,quality1 in cooperation with the recipients of grants under this subsection1 shall conduct an evaluation of the pilot program under this subsection1 beginning #a year after the date on which a grant is first awarded under this subsection4 ,the ,director of the ,center for ,behavioral ,health ,statistics and ,quality1 in coordination with the ,director of the ,center for ,substance ,abuse ,treatment1 not later than #abj days after completion of such evaluation1 shall submit to the relevant ,committees of the ,senate and the ,house of ,representatives a report on such evaluation4 7,b7 ,contents ,the report to ,congress under subparagraph 7,a7 shall include1 at a minimum1 outcomes information from the pilot program1 including any resulting reductions in the use of alcohol and other drugs1 engagement in treatment services1 retention in the appropriate level and duration of services1 increased access to the use of drugs approved by the ,food and ,drug ,administration for the treatment of substance use disorders in combination with counseling1 and other appropriate measures4 7#f7 ,definition of ,state substance abuse agency ,for purposes of this subsection1 the term ,state substance abuse agency means1 with respect to a ,state1 the agency in such ,state that manages the substance abuse prevention and treatment block grant program under part ,b of title ,,xix4 7s7 ,funding 7#a7 ,in general ,for the purpose of carrying out this section1 there are authorized to be appropriated #ae1ijj1jjj for each of fiscal years #bjaf through #bjbj4 7#b7 ,limitation ,of the amounts made available under paragraph 7#a7 to carry out this section1 not more than #be percent may be used each fiscal year to carry out subsection 7r74 4 #ejb4 ,report on grants for family-based substance abuse treatment ,section #bibe of the ,omnibus ,crime ,control and ,safe ,streets ,act of #aifh 7#db ,u4,s4,c4 #cgigs-#d7 is amended-- 7#a7 by striking ,an entity and inserting 7a7 ,entity ,reports4--,an entity2 and 7#b7 by adding at the end the following3 7b7 ,attorney general report on family-,based substance abuse treatment ,the ,attorney ,general shall submit to ,congress an annual report that describes the number of grants awarded under section #biba7a7 and how such grants are used by the recipients for family-based substance abuse treatment programs that serve as alternatives to incarceration for custodial parents to receive treatment and services as a family4 4 #ejc4 ,veterans' treatment courts ,section #biia7;j77#a77;,b77ii7 of title ,i of the ,omnibus ,crime ,control and ,safe ,streets ,act of #aifh 7#db ,u4,s4,c4 #cgig;aa7j77#a77;,b77ii771 as amended by the ,comprehensive ,justice and ,mental ,health ,act of #bjae 7,s4 #iic1 #aadth ,congress71 is amended-- 7#a7 by inserting 7,i7 after 7ii72 7#b7 in subclause 7,i71 as so designated1 by striking the period and inserting 2 or2 and 7#c7 by adding at the end the following3 7,,ii7 was discharged or released from such service under dishonorable conditions1 if the reason for that discharge or release1 if known1 is attributable to a substance use disorder4 4 ,,vi ,incentivizing ,state comprehensive initiatives to address prescription opioid and heroin abuse #fja4 ,state demonstration grants for comprehensive opioid abuse response 7a7 ,definitions ,in this section-- 7#a7 the term dispenser has the meaning given the term in section #ajb of the ,controlled ,substances ,act 7#ba ,u4,s4,c4 #hjb72 7#b7 the term prescriber means a dispenser who prescribes a controlled substance1 or the agent of such a dispenser2 7#c7 the term prescriber of a schedule ,,ii1 ,,iii1 or ,,iv controlled substance does not include a prescriber of a schedule ,,ii1 ,,iii1 or ,,iv controlled substance that dispenses the substance-- 7,a7 for use on the premises on which the substance is dispensed2 7,b7 in a hospital emergency room1 when the substance is in short supply2 7,c7 for a certified opioid treatment program2 or 7,d7 in other situations as the ,attorney ,general may reasonably determine2 and 7#d7 the term schedule ,,ii1 ,,iii1 or ,,iv controlled substance means a controlled substance that is listed on schedule ,,ii1 schedule ,,iii1 or schedule ,,iv of section #bjb7;c7 of the ,controlled ,substances ,act 7#ba ,u4,s4,c4 #hab7;c774 7b7 ,planning and implementation grants 7#a7 ,in general ,the ,attorney ,general1 in coordination with the ,secretary of ,health and ,human ,services and in consultation with the ,director of the ,office of ,national ,drug ,control ,policy1 may award grants to ,states1 and combinations thereof1 to prepare a comprehensive plan for and implement an integrated opioid abuse response initiative4 7#b7 ,purposes ,a ,state receiving a grant under this section shall establish a comprehensive response to opioid abuse1 which shall include-- 7,a7 prevention and education efforts around heroin and opioid use1 treatment1 and recovery1 including education of residents1 medical students1 and physicians and other prescribers of schedule ,,ii1 ,,iii1 or ,,iv controlled substances on relevant prescribing guidelines and the prescription drug monitoring program of the ,state2 7,b7 a comprehensive prescription drug monitoring program to track dispensing of schedule ,,ii1 ,,iii1 or ,,iv controlled substances1 which shall-- 7i7 provide for data sharing with other ,states by statute1 regulation1 or interstate agreement2 and 7ii7 allow for access to all individuals authorized by the ,state to write prescriptions for schedule ,,ii1 ,,iii1 or ,,iv controlled substances on the prescription drug monitoring program of the ,state2 7,c7 developing1 implementing1 or expanding prescription drug and opioid addiction treatment programs by-- 7i7 expanding programs for medication assisted treatment of prescription drug and opioid addiction1 including training for treatment and recovery support providers2 7ii7 developing1 implementing1 or expanding programs for behavioral health therapy for individuals who are in treatment for prescription drug and opioid addiction2 7iii7 developing1 implementing1 or expanding programs to screen individuals who are in treatment for prescription drug and opioid addiction for hepatitis ,c and ,,hiv1 and provide treatment for those individuals if clinically appropriate2 or 7iv7 developing1 implementing1 or expanding programs that provide screening1 early intervention1 and referral to treatment 7commonly known as ,,sbirt7 to teenagers and young adults in primary care1 middle schools1 high schools1 universities1 school-based health centers1 and other community-based health care settings frequently accessed by teenagers or young adults2 and 7,d7 developing1 implementing1 and expanding programs to prevent overdose death from prescription medications and opioids4 7#c7 ,planning grant applications 7,a7 ,application 7i7 ,in general ,a ,state seeking a planning grant under this section to prepare a comprehensive plan for an integrated opioid abuse response initiative shall submit to the ,attorney ,general an application in such form1 and containing such information1 as the ,attorney ,general may require4 7ii7 ,requirements ,an application for a planning grant under this section shall1 at a minimum1 include-- 7,i7 a budget and a budget justification for the activities to be carried out using the grant2 7,,ii7 a description of the activities proposed to be carried out using the grant1 including a schedule for completion of such activities2 7,,iii7 outcome measures that will be used to measure the effectiveness of the programs and initiatives to address opioids2 and 7,,iv7 a description of the personnel necessary to complete such activities4 7,b7 ,period2 nonrenewability ,a planning grant under this section shall be for a period of #a year4 ,a ,state may not receive more than #a planning grant under this section4 7,c7 ,strategic plan and program implementation plan ,a ,state receiving a planning grant under this section shall develop a strategic plan and a program implementation plan4 7#d7 ,implementation grants 7,a7 ,application ,a ,state seeking an implementation grant under this section to implement a comprehensive strategy for addressing opioid abuse shall submit to the ,attorney ,general an application in such form1 and containing such information1 as the ,attorney ,general may require4 7,b7 ,use of funds ,a ,state that receives an implementation grant under this section shall use the grant for the cost of carrying out an integrated opioid abuse response program in accordance with this section1 including for technical assistance1 training1 and administrative expenses4 7,c7 ,requirements ,an integrated opioid abuse response program carried out using an implementation grant under this section shall-- 7i7 require that each prescriber of a schedule ,,ii1 ,,iii1 or ,,iv controlled substance in the ,state-- 7,i7 registers with the prescription drug monitoring program of the ,state2 and 7,,ii7 consults the prescription drug monitoring program database of the ,state before prescribing a schedule ,,ii1 ,,iii1 or ,,iv controlled substance2 7ii7 require that each dispenser of a schedule ,,ii1 ,,iii1 or ,,iv controlled substance in the ,state-- 7,i7 registers with the prescription drug monitoring program of the ,state2 7,,ii7 consults the prescription drug monitoring program database of the ,state before dispensing a schedule ,,ii1 ,,iii1 or ,,iv controlled substance2 and 7,,iii7 reports to the prescription drug monitoring program of the ,state1 at a minimum1 each instance in which a schedule ,,ii1 ,,iii1 or ,,iv controlled substance is dispensed1 with limited exceptions1 as defined by the ,state1 which shall indicate the prescriber by name and ,national ,provider ,identifier2 7iii7 require that1 not fewer than #d times each year1 the ,state agency or agencies that administer the prescription drug monitoring program of the ,state prepare and provide to each prescriber of a schedule ,,ii1 ,,iii1 or ,,iv controlled substance an informational report that shows how the prescribing patterns of the prescriber compare to prescribing practices of the peers of the prescriber and expected norms2 7iv7 if informational reports provided to a prescriber under clause 7iii7 indicate that the prescriber is repeatedly falling outside of expected norms or standard practices for the prescriber's field1 direct the prescriber to educational resources on appropriate prescribing of controlled substances2 7v7 ensure that the prescriber licensing board of the ,state receives a report describing any prescribers that repeatedly fall outside of expected norms or standard practices for the prescriber's field1 as described in clause 7iii72 7vi7 require consultation with the ,single ,state ,authority for ,substance ,abuse 7as defined in section #bja7;e7 of the ,second ,chance ,act of #bjjg 7#db ,u4,s4,c4 #ageba7;e7772 and 7vii7 establish requirements for how data will be collected and analyzed to determine the effectiveness of the program4 7,d7 ,period ,an implementation grant under this section shall be for a period of #b years4 7#e7 ,priority considerations ,in awarding planning and implementation grants under this section1 the ,attorney ,general shall give priority to a ,state that-- 7,a7 7i7 provides civil liability protection for first responders1 health professionals1 and family members who have received appropriate training in the administration of naloxone in administering naloxone to counteract opioid overdoses2 and 7ii7 submits to the ,attorney ,general a certification by the attorney general of the ,state that the attorney general has-- 7,i7 reviewed any applicable civil liability protection law to determine the applicability of the law with respect to first responders1 health care professionals1 family members1 and other individuals who-- 7aa7 have received appropriate training in the administration of naloxone2 and 7bb7 may administer naloxone to individuals reasonably believed to be suffering from opioid overdose2 and 7,,ii7 concluded that the law described in subclause 7,i7 provides adequate civil liability protection applicable to such persons2 7,b7 has in effect legislation or implements a policy under which the ,state shall not terminate1 but may suspend1 enrollment under the ,state plan for medical assistance under title ,,xix of the ,social ,security ,act 7#db ,u4,s4,c4 #acif et seq47 for an individual who is incarcerated for a period of fewer than #b years2 7,c7 has a process for enrollment in services and benefits necessary by criminal justice agencies to initiate or continue treatment in the community1 under which an individual who is incarcerated may1 while incarcerated1 enroll in services and benefits that are necessary for the individual to continue treatment upon release from incarceration2 7,d7 ensures the capability of data sharing with other ,states1 such as by making data available to a prescription monitoring hub2 7,e7 ensures that data recorded in the prescription drug monitoring program database of the ,state is available within #bd hours1 to the extent possible2 and 7,f7 ensures that the prescription drug monitoring program of the ,state notifies prescribers and dispensers of schedule ,,ii1 ,,iii1 or ,,iv controlled substances when overuse or misuse of such controlled substances by patients is suspected4 7c7 ,authorization of ,funding ,for each of fiscal years #bjaf through #bjbj1 the ,attorney ,general may use1 from any unobligated balances made available under the heading ,,general ,,administration to the ,department of ,justice in an appropriation ,act1 such amounts as are necessary to carry out this section1 not to exceed #e1jjj1jjj per fiscal year4 ,,vii ,miscellaneous #gja4 ,,gao report on ,,imd exclusion 7a7 ,definition ,in this section1 the term ,medicaid ,institutions for ,mental ,disease exclusion means the prohibition on ,federal matching payments under ,medicaid for patients who have attained age #bb1 but have not attained age #fe1 in an institution for mental diseases under subparagraph 7,b7 of the matter following subsection 7a7 of section #aije of the ,social ,security ,act 7#db ,u4,s4,c4 #acif;d7 and subsection 7i7 of such section4 7b7 ,report required ,not later than #a year after the date of enactment of this ,act1 the ,comptroller ,general of the ,united ,states shall submit to ,congress a report on the impact that the ,medicaid ,institutions for ,mental ,disease exclusion has on access to treatment for individuals with a substance use disorder4 7c7 ,elements ,the report required under subsection 7b7 shall include a review of what is known regarding-- 7#a7 ,medicaid beneficiary access to substance use disorder treatments in institutions for mental disease2 and 7#b7 the quality of care provided to ,medicaid beneficiaries treated in and outside of institutions for mental disease for substance use disorders4 #gjb4 ,funding ,part ,,ii of title ,i of the ,omnibus ,crime ,control and ,safe ,streets ,act of #aifh 7#db ,u4,s4,c4 #cgig;cc et seq471 as amended by section #dja1 is amended by adding at the end the following3 #biii;,e4 ,funding ,there are authorized to be appropriated to the ,attorney ,general and the ,secretary of ,health and ,human ,services to carry out this part #fb1jjj1jjj for each of fiscal years #bjaf through #bjbj4 4 #gjc4 ,conforming amendments ,part ,,ii of title ,i of the ,omnibus ,crime ,control and ,safe ,streets ,act of #aifh 7#db ,u4,s4,c4 #cgig;cc et seq47 is amended-- 7#a7 in the part heading1 by striking ,,confronting ,,use ,,of ,,methamphetamine and inserting ,,comprehensive ,,addiction ,,and ,,recovery2 and 7#b7 in section #biif7;a77#a71 by striking this part and inserting this section4 #gjd4 ,grant accountability 7a7 ,grants under part ,,ii of title ,i of the ,omnibus ,crime ,control and ,safe ,streets ,act of #aifh ,part ,,ii of title ,i of the ,omnibus ,crime ,control and ,safe ,streets ,act of #aifh 7#db ,u4,s4,c4 #cgig;cc et seq472 as amended by section #gjb1 is amended by adding at the end the following3 #biii;,f4 ,grant accountability 7a7 ,definitions ,in this section-- 7#a7 the term applicable committees-- 7,a7 with respect to the ,attorney ,general and any other official of the ,department of ,justice1 means-- 7i7 the ,committee on the ,judiciary of the ,senate2 and 7ii7 the ,committee on the ,judiciary of the ,house of ,representatives2 and 7,b7 with respect to the ,secretary of ,health and ,human ,services and any other official of the ,department of ,health and ,human ,services1 means-- 7i7 the ,committee on ,health1 ,education1 ,labor1 and ,pensions of the ,senate2 and 7ii7 the ,committee on ,energy and ,commerce of the ,house of ,representatives2 7#b7 the term covered agency means-- 7,a7 the ,department of ,justice2 and 7,b7 the ,department of ,health and ,human ,services2 and 7#c7 the term covered official means-- 7,a7 the ,attorney ,general2 and 7,b7 the ,secretary of ,health and ,human ,services4 7b7 ,accountability ,all grants awarded by a covered official under this part shall be subject to the following accountability provisions3 7#a7 ,audit requirement 7,a7 ,definition ,in this paragraph1 the term unresolved audit finding means a finding in the final audit report of the ,inspector ,general of a covered agency that the audited grantee has utilized grant funds for an unauthorized expenditure or otherwise unallowable cost that is not closed or resolved within #ab months after the date on which the final audit report is issued4 7,b7 ,audit ,beginning in the first fiscal year beginning after the date of enactment of this section1 and in each fiscal year thereafter1 the ,inspector ,general of a covered agency shall conduct audits of recipients of grants awarded by the applicable covered official under this part to prevent waste1 fraud1 and abuse of funds by grantees4 ,the ,inspector ,general shall determine the appropriate number of grantees to be audited each year4 7,c7 ,mandatory exclusion ,a recipient of grant funds under this part that is found to have an unresolved audit finding shall not be eligible to receive grant funds under this part during the first #b fiscal years beginning after the end of the #ab-month period described in subparagraph 7,a74 7,d7 ,priority ,in awarding grants under this part1 a covered official shall give priority to eligible applicants that did not have an unresolved audit finding during the #c fiscal years before submitting an application for a grant under this part4 7,e7 ,reimbursement ,if an entity is awarded grant funds under this part during the #b-;fiscal-year period during which the entity is barred from receiving grants under subparagraph 7,c71 the covered official that awarded the grant funds shall-- 7i7 deposit an amount equal to the amount of the grant funds that were improperly awarded to the grantee into the ,general ,fund of the ,treasury2 and 7ii7 seek to recoup the costs of the repayment to the fund from the grant recipient that was erroneously awarded grant funds4 7#b7 ,nonprofit organization requirements 7,a7 ,definition ,for purposes of this paragraph and the grant programs under this part1 the term nonprofit organization means an organization that is described in section #eja7;c77#c7 of the ,internal ,revenue ,code of #aihf and is exempt from taxation under section #eja7;a7 of such ,code4 7,b7 ,prohibition ,a covered official may not award a grant under this part to a nonprofit organization that holds money in offshore accounts for the purpose of avoiding paying the tax described in section #eaa7;a7 of the ,internal ,revenue ,code of #aihf4 7,c7 ,disclosure ,each nonprofit organization that is awarded a grant under this part and uses the procedures prescribed in regulations to create a rebuttable presumption of reasonableness for the compensation of its officers1 directors1 trustees1 and key employees1 shall disclose to the applicable covered official1 in the application for the grant1 the process for determining such compensation1 including the independent persons involved in reviewing and approving such compensation1 the comparability data used1 and contemporaneous substantiation of the deliberation and decision4 ,upon request1 a covered official shall make the information disclosed under this subparagraph available for public inspection4 7#c7 ,conference expenditures 7,a7 ,limitation ,no amounts made available to a covered official under this part may be used by the covered official1 or by any individual or entity awarded discretionary funds through a cooperative agreement under this part1 to host or support any expenditure for conferences that uses more than #bj1jjj in funds made available by the covered official1 unless the covered official provides prior written authorization that the funds may be expended to host the conference4 7,b7 ,written authorization ,written authorization under subparagraph 7,a7 shall include a written estimate of all costs associated with the conference1 including the cost of all food1 beverages1 audio-visual equipment1 honoraria for speakers1 and entertainment4 7,c7 ,report 7i7 ,department of ,justice ,the ,deputy ,attorney ,general shall submit to the applicable committees an annual report on all conference expenditures approved by the ,attorney ,general under this paragraph4 7ii7 ,department of ,health and ,human ,services ,the ,deputy ,secretary of ,health and ,human ,services shall submit to the applicable committees an annual report on all conference expenditures approved by the ,secretary of ,health and ,human ,services under this paragraph4 7#d7 ,annual certification ,beginning in the first fiscal year beginning after the date of enactment of this section1 each covered official shall submit to the applicable committees an annual certification-- 7,a7 indicating whether-- 7i7 all audits issued by the ,office of the ,inspector ,general of the applicable agency under paragraph 7#a7 have been completed and reviewed by the appropriate ,assistant ,attorney ,general or ,director1 or the appropriate official of the ,department of ,health and ,human ,services1 as applicable2 7ii7 all mandatory exclusions required under paragraph 7#a77;,c7 have been issued2 and 7iii7 all reimbursements required under paragraph 7#a77;,e7 have been made2 and 7,b7 that includes a list of any grant recipients excluded under paragraph 7#a7 from the previous year4 7c7 ,preventing duplicative grants 7#a7 ,in general ,before a covered official awards a grant to an applicant under this part1 the covered official shall compare potential grant awards with other grants awarded under this part by the covered official to determine if duplicate grant awards are awarded for the same purpose4 7#b7 ,report ,if a covered official awards duplicate grants to the same applicant for the same purpose1 the covered official shall submit to the applicable committees a report that includes-- 7,a7 a list of all duplicate grants awarded1 including the total dollar amount of any duplicate grants awarded2 and 7,b7 the reason the covered official awarded the duplicate grants4 4 7b7 ,other grants 7#a7 ,definitions ,in this subsection-- 7,a7 the term applicable committees-- 7i7 with respect to the ,attorney ,general and any other official of the ,department of ,justice1 means-- 7,i7 the ,committee on the ,judiciary of the ,senate2 and 7,,ii7 the ,committee on the ,judiciary of the ,house of ,representatives2 and 7ii7 with respect to the ,secretary of ,health and ,human ,services and any other official of the ,department of ,health and ,human ,services1 means-- 7,i7 the ,committee on ,health1 ,education1 ,labor1 and ,pensions of the ,senate2 and 7,,ii7 the ,committee on ,energy and ,commerce of the ,house of ,representatives2 7,b7 the term covered agency means-- 7i7 the ,department of ,justice2 and 7ii7 the ,department of ,health and ,human ,services2 7,c7 the term covered grant means a grant under section #bja1 #cjb1 or #fja of this ,act or section #ejh of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bij;bb-#a7 7as amended by section #eja of this ,act72 and 7,d7 the term covered official means-- 7i7 the ,attorney ,general2 and 7ii7 the ,secretary of ,health and ,human ,services4 7#b7 ,accountability ,all covered grants awarded by a covered official shall be subject to the following accountability provisions3 7,a7 ,audit requirement 7i7 ,definition ,in this subparagraph1 the term unresolved audit finding means a finding in the final audit report of the ,inspector ,general of a covered agency that the audited grantee has utilized grant funds for an unauthorized expenditure or otherwise unallowable cost that is not closed or resolved within #ab months after the date on which the final audit report is issued4 7ii7 ,audit ,beginning in the first fiscal year beginning after the date of enactment of this ,act1 and in each fiscal year thereafter1 the ,inspector ,general of a covered agency shall conduct audits of recipients of covered grants awarded by the applicable covered official to prevent waste1 fraud1 and abuse of funds by grantees4 ,the ,inspector ,general shall determine the appropriate number of grantees to be audited each year4 7iii7 ,mandatory exclusion ,a recipient of covered grant funds that is found to have an unresolved audit finding shall not be eligible to receive covered grant funds during the first #b fiscal years beginning after the end of the #ab-month period described in clause 7i74 7iv7 ,priority ,in awarding covered grants1 a covered official shall give priority to eligible applicants that did not have an unresolved audit finding during the #c fiscal years before submitting an application for a covered grant4 7v7 ,reimbursement ,if an entity is awarded covered grant funds during the #b-;fiscal-year period during which the entity is barred from receiving grants under clause 7iii71 the covered official that awarded the funds shall-- 7,i7 deposit an amount equal to the amount of the grant funds that were improperly awarded to the grantee into the ,general ,fund of the ,treasury2 and 7,,ii7 seek to recoup the costs of the repayment to the fund from the grant recipient that was erroneously awarded grant funds4 7,b7 ,nonprofit organization requirements 7i7 ,definition ,for purposes of this subparagraph and the covered grant programs1 the term nonprofit organization means an organization that is described in section #eja7;c77#c7 of the ,internal ,revenue ,code of #aihf and is exempt from taxation under section #eja7;a7 of such ,code4 7ii7 ,prohibition ,a covered official may not award a covered grant to a nonprofit organization that holds money in offshore accounts for the purpose of avoiding paying the tax described in section #eaa7;a7 of the ,internal ,revenue ,code of #aihf4 7iii7 ,disclosure ,each nonprofit organization that is awarded a covered grant and uses the procedures prescribed in regulations to create a rebuttable presumption of reasonableness for the compensation of its officers1 directors1 trustees1 and key employees1 shall disclose to the applicable covered official1 in the application for the grant1 the process for determining such compensation1 including the independent persons involved in reviewing and approving such compensation1 the comparability data used1 and contemporaneous substantiation of the deliberation and decision4 ,upon request1 a covered official shall make the information disclosed under this clause available for public inspection4 7,c7 ,conference expenditures 7i7 ,limitation ,no amounts made available to a covered official under a covered grant program may be used by the covered official1 or by any individual or entity awarded discretionary funds through a cooperative agreement under a covered grant program1 to host or support any expenditure for conferences that uses more than #bj1jjj in funds made available by the covered official1 unless the covered official provides prior written authorization that the funds may be expended to host the conference4 7ii7 ,written authorization ,written authorization under clause 7i7 shall include a written estimate of all costs associated with the conference1 including the cost of all food1 beverages1 audio-visual equipment1 honoraria for speakers1 and entertainment4 7iii7 ,report 7,i7 ,department of ,justice ,the ,deputy ,attorney ,general shall submit to the applicable committees an annual report on all conference expenditures approved by the ,attorney ,general under this subparagraph4 7,,ii7 ,department of ,health and ,human ,services ,the ,deputy ,secretary of ,health and ,human ,services shall submit to the applicable committees an annual report on all conference expenditures approved by the ,secretary of ,health and ,human ,services under this subparagraph4 7,d7 ,annual certification ,beginning in the first fiscal year beginning after the date of enactment of this ,act1 each covered official shall submit to the applicable committees an annual certification-- 7i7 indicating whether-- 7,i7 all audits issued by the ,office of the ,inspector ,general of the applicable agency under subparagraph 7,a7 have been completed and reviewed by the appropriate ,assistant ,attorney ,general or ,director1 or the appropriate official of the ,department of ,health and ,human ,services1 as applicable2 7,,ii7 all mandatory exclusions required under subparagraph 7,a77iii7 have been issued2 and 7,,iii7 all reimbursements required under subparagraph 7,a77v7 have been made2 and 7ii7 that includes a list of any grant recipients excluded under subparagraph 7,a7 from the previous year4 7#c7 ,preventing duplicative grants 7,a7 ,in general ,before a covered official awards a covered grant to an applicant1 the covered official shall compare potential grant awards with other covered grants awarded by the covered official to determine if duplicate grant awards are awarded for the same purpose4 7,b7 ,report ,if a covered official awards duplicate grants to the same applicant for the same purpose1 the covered official shall submit to the applicable committees a report that includes-- 7i7 a list of all duplicate grants awarded1 including the total dollar amount of any duplicate grants awarded2 and 7ii7 the reason the covered official awarded the duplicate grants4 #gje4 ,programs to prevent prescription drug abuse under the ,medicare program 7a7 ,drug ,management ,program for ,at-,risk ,beneficiaries 7#a7 ,in general ,section #ahfj;,d-#d7;c7 of the ,social ,security ,act 7#db ,u4,s4,c4 #aciew-#ajd7;c77 is amended by adding at the end the following3 7#e7 ,drug management program for at-risk beneficiaries 7,a7 ,authority to establish ,a ,,pdp sponsor may establish a drug management program for at-risk beneficiaries under which1 subject to subparagraph 7,b71 the ,,pdp sponsor may1 in the case of an at-risk beneficiary for prescription drug abuse who is an enrollee in a prescription drug plan of such ,,pdp sponsor1 limit such beneficiary's access to coverage for frequently abused drugs under such plan to frequently abused drugs that are prescribed for such beneficiary by a prescriber 7or prescribers7 selected under subparagraph 7,d71 and dispensed for such beneficiary by a pharmacy 7or pharmacies7 selected under such subparagraph4 7,b7 ,requirement for notices 7i7 ,in general ,a ,,pdp sponsor may not limit the access of an at-risk beneficiary for prescription drug abuse to coverage for frequently abused drugs under a prescription drug plan until such sponsor-- 7,i7 provides to the beneficiary an initial notice described in clause 7ii7 and a second notice described in clause 7iii72 and 7,,ii7 verifies with the providers of the beneficiary that the beneficiary is an at-risk beneficiary for prescription drug abuse1 as described in subparagraph 7,c77iv74 7ii7 ,initial notice ,an initial written notice described in this clause is a notice that provides to the beneficiary-- 7,i7 notice that the ,,pdp sponsor has identified the beneficiary as potentially being an at-risk beneficiary for prescription drug abuse2 7,,ii7 information1 when possible1 describing ,state and ,federal public health resources that are designed to address prescription drug abuse to which the beneficiary may have access1 including substance use disorder treatment services1 addiction treatment services1 mental health services1 and other counseling services2 7,,iii7 a request for the beneficiary to submit to the ,,pdp sponsor preferences for which prescribers and pharmacies the beneficiary would prefer the ,,pdp sponsor to select under subparagraph 7,d7 in the case that the beneficiary is identified as an at-risk beneficiary for prescription drug abuse as described in clause 7iii77,i72 7,,iv7 an explanation of the meaning and consequences of the identification of the beneficiary as potentially being an at-risk beneficiary for prescription drug abuse1 including an explanation of the drug management program established by the ,,pdp sponsor pursuant to subparagraph 7,a72 7,v7 clear instructions that explain how the beneficiary can contact the ,,pdp sponsor in order to submit to the ,,pdp sponsor the preferences described in subclause 7,,iv7 and any other communications relating to the drug management program for at-risk beneficiaries established by the ,,pdp sponsor2 7,,vi7 contact information for other organizations that can provide the beneficiary with information regarding drug management program for at-risk beneficiaries 7similar to the information provided by the ,secretary in other standardized notices to part ,d eligible individuals enrolled in prescription drug plans under this part72 and 7,,vii7 notice that the beneficiary has a right to an appeal pursuant to subparagraph 7,e74 7iii7 ,second notice ,a second written notice described in this clause is a notice that provides to the beneficiary notice-- 7,i7 that the ,,pdp sponsor has identified the beneficiary as an at-risk beneficiary for prescription drug abuse2 7,,ii7 that such beneficiary has been sent1 or informed of1 such identification in the initial notice and is now subject to the requirements of the drug management program for at-risk beneficiaries established by such ,,pdp sponsor for such plan2 7,,iii7 of the prescriber and pharmacy selected for such individual under subparagraph 7,d72 7,,iv7 of1 and information about1 the right of the beneficiary to a reconsideration and an appeal under subsection 7h7 of such identification and the prescribers and pharmacies selected2 7,v7 that the beneficiary can1 in the case that the beneficiary has not previously submitted to the ,,pdp sponsor preferences for which prescribers and pharmacies the beneficiary would prefer the ,,pdp sponsor select under subparagraph 7,d71 submit such preferences to the ,,pdp sponsor2 and 7,,vi7 that includes clear instructions that explain how the beneficiary can contact the ,,pdp sponsor in order to submit to the ,,pdp sponsor the preferences described in subclause 7,v74 7iv7 ,timing of notices 7,i7 ,in general ,subject to subclause 7,,ii71 a second written notice described in clause 7iii7 shall be provided to the beneficiary on a date that is not less than #cj days after an initial notice described in clause 7ii7 is provided to the beneficiary4 7,,ii7 ,exception ,in the case that the ,,pdp sponsor1 in conjunction with the ,secretary1 determines that concerns identified through rulemaking by the ,secretary regarding the health or safety of the beneficiary or regarding significant drug diversion activities require the ,,pdp sponsor to provide a second notice described in clause 7iii7 to the beneficiary on a date that is earlier than the date described in subclause 7,,ii71 the ,,pdp sponsor may provide such second notice on such earlier date4 7,,iii7 ,form of notice ,the written notices under clauses 7ii7 and 7iii7 shall be in a format determined appropriate by the ,secretary1 taking into account beneficiary preferences4 7,c7 ,at-risk beneficiary for prescription drug abuse 7i7 ,in general ,for purposes of this paragraph1 the term at-risk beneficiary for prescription drug abuse means a part ,d eligible individual who is not an exempted individual described in clause 7ii7 and-- 7,i7 who is identified through criteria developed by the ,secretary in consultation with ,,pdp sponsors and other stakeholders described in subsection section 7g77#b77;,a7 of the ,comprehensive ,addiction and ,recovery ,act of #bjaf based on clinical factors indicating misuse or abuse of prescription drugs described in subparagraph 7,g71 including dosage1 quantity1 duration of use1 number of and reasonable access to prescribers1 and number of and reasonable access to pharmacies used to obtain such drug2 or 7,,ii7 with respect to whom the ,,pdp sponsor of a prescription drug plan1 upon enrolling such individual in such plan1 received notice from the ,secretary that such individual was identified under this paragraph to be an at-risk beneficiary for prescription drug abuse under a prescription drug plan in which such individual was previously enrolled and such identification has not been terminated under subparagraph 7,f74 7ii7 ,exempted individual described ,an exempted individual described in this clause is an individual who-- 7,i7 receives hospice care under this title2 7,,ii7 resides in a long-term care facility1 a facility described in section #aije7;d71 or other facility under contract with a single pharmacy2 or 7,,iii7 the ,secretary elects to treat as an exempted individual for purposes of clause 7i74 7iii7 ,program size ,the ,secretary shall establish policies1 including the criteria developed under clause 7i77,i7 and the exemptions under clause 7ii77,,iii71 to ensure that the population of enrollees in a drug management program for at-risk beneficiaries operated by a prescription drug plan can be effectively managed by such plans4 7iv7 ,clinical contact ,with respect to each at-risk beneficiary for prescription drug abuse enrolled in a prescription drug plan offered by a ,,pdp sponsor1 the ,,pdp sponsor shall contact the beneficiary's providers who have prescribed frequently abused drugs regarding whether prescribed medications are appropriate for such beneficiary's medical conditions4 7,d7 ,selection of prescribers 7i7 ,in general ,with respect to each at-risk beneficiary for prescription drug abuse enrolled in a prescription drug plan offered by such sponsor1 a ,,pdp sponsor shall1 based on the preferences submitted to the ,,pdp sponsor by the beneficiary pursuant to clauses 7ii77,,iii7 and 7iii77,v7 of subparagraph 7,b7 if applicable1 select-- 7,i7 one1 or1 if the ,,pdp sponsor reasonably determines it necessary to provide the beneficiary with reasonable access under clause 7ii71 more than one1 individual who is authorized to prescribe frequently abused drugs 7referred to in this paragraph as a prescriber7 who may write prescriptions for such drugs for such beneficiary2 and 7,,ii7 one1 or1 if the ,,pdp sponsor reasonably determines it necessary to provide the beneficiary with reasonable access under clause 7ii71 more than one1 pharmacy that may dispense such drugs to such beneficiary4 7ii7 ,reasonable access ,in making the selection under this subparagraph1 a ,,pdp sponsor shall ensure1 taking into account geographic location1 beneficiary preference1 impact on cost-sharing1 and reasonable travel time1 that the beneficiary continues to have reasonable access to drugs described in subparagraph 7,g71 including-- 7,i7 for individuals with multiple residences2 and 7,,ii7 in the case of natural disasters and similar emergency situations4 7iii7 ,beneficiary preferences 7,i7 ,in general ,if an at-risk beneficiary for prescription drug abuse submits preferences for which in-network prescribers and pharmacies the beneficiary would prefer the ,,pdp sponsor select in response to a notice under subparagraph 7,b71 the ,,pdp sponsor shall-- 7aa7 review such preferences2 7bb7 select or change the selection of a prescriber or pharmacy for the beneficiary based on such preferences2 and 7cc7 inform the beneficiary of such selection or change of selection4 7,,ii7 ,exception ,in the case that the ,,pdp sponsor determines that a change to the selection of a prescriber or pharmacy under item 7bb7 by the ,,pdp sponsor is contributing or would contribute to prescription drug abuse or drug diversion by the beneficiary1 the ,,pdp sponsor may change the selection of a prescriber or pharmacy for the beneficiary4 ,if the ,,pdp sponsor changes the selection pursuant to the preceding sentence1 the ,,pdp sponsor shall provide the beneficiary with-- 7aa7 at least #cj days written notice of the change of selection2 and 7bb7 a rationale for the change4 7,,iii7 ,timing ,an at-risk beneficiary for prescription drug abuse may choose to express their prescriber and pharmacy preference and communicate such preference to their ,,pdp sponsor at any date while enrolled in the program1 including after a second notice under subparagraph 7,b77iii7 has been provided4 7iv7 ,confirmation ,before selecting a prescriber or pharmacy under this subparagraph1 a ,,pdp sponsor must notify the prescriber and pharmacy that the beneficiary involved has been identified for inclusion in the drug management program for at-risk beneficiaries and that the prescriber and pharmacy has been selected as the beneficiary's designated prescriber and pharmacy4 7,e7 ,appeals ,the identification of an individual as an at-risk beneficiary for prescription drug abuse under this paragraph1 a coverage determination made under a drug management program for at-risk beneficiaries1 and the selection of a prescriber or pharmacy under subparagraph 7,d7 with respect to such individual shall be subject to an expedited reconsideration and appeal pursuant to subsection 7h74 7,f7 ,termination of identification 7i7 ,in general ,the ,secretary shall develop standards for the termination of identification of an individual as an at-risk beneficiary for prescription drug abuse under this paragraph4 ,under such standards such identification shall terminate as of the earlier of-- 7,i7 the date the individual demonstrates that the individual is no longer likely1 in the absence of the restrictions under this paragraph1 to be an at-risk beneficiary for prescription drug abuse described in subparagraph 7,c77i72 or 7,,ii7 the end of such maximum period of identification as the ,secretary may specify4 7ii7 ,rule of construction ,nothing in clause 7i7 shall be construed as preventing a plan from identifying an individual as an at-risk beneficiary for prescription drug abuse under subparagraph 7,c77i7 after such termination on the basis of additional information on drug use occurring after the date of notice of such termination4 7,g7 ,frequently abused drug ,for purposes of this subsection1 the term frequently abused drug means a drug that is determined by the ,secretary to be frequently abused or diverted and that is-- 7i7 a ,controlled ,drug ,substance in ,schedule ,,cii2 or 7ii7 within the same class or category of drugs as a ,controlled ,drug ,substance in ,schedule ,,cii1 as determined through notice and comment rulemaking4 7,h7 ,data disclosure 7i7 ,data on decision to impose limitation ,in the case of an at-risk beneficiary for prescription drug abuse 7or an individual who is a potentially at-risk beneficiary for prescription drug abuse7 whose access to coverage for frequently abused drugs under a prescription drug plan has been limited by a ,,pdp sponsor under this paragraph1 the ,secretary shall establish rules and procedures to require such ,,pdp sponsor to disclose data1 including necessary individually identifiable health information1 about the decision to impose such limitations and the limitations imposed by the ,,pdp sponsor under this part4 7ii7 ,data to reduce fraud1 abuse1 and waste ,the ,secretary shall establish rules and procedures to require ,,pdp sponsors operating a drug management program for at-risk beneficiaries under this paragraph to provide the ,secretary with such data as the ,secretary determines appropriate for purposes of identifying patterns of prescription drug utilization for plan enrollees that are outside normal patterns and that may indicate fraudulent1 medically unnecessary1 or unsafe use4 7,i7 ,sharing of information for subsequent plan enrollments ,the ,secretary shall establish procedures under which ,,pdp sponsors who offer prescription drug plans shall share information with respect to individuals who are at-risk beneficiaries for prescription drug abuse 7or individuals who are potentially at-risk beneficiaries for prescription drug abuse7 and enrolled in a prescription drug plan and who subsequently disenroll from such plan and enroll in another prescription drug plan offered by another ,,pdp sponsor4 7,j7 ,privacy issues ,prior to the implementation of the rules and procedures under this paragraph1 the ,secretary shall clarify privacy requirements1 including requirements under the regulations promulgated pursuant to section #bfd7;c7 of the ,health ,insurance ,portability and ,accountability ,act of #aiif 7#db ,u4,s4,c4 #acbj;d-#b note71 related to the sharing of data under subparagraphs 7,h7 and 7,i7 by ,,pdp sponsors4 ,such clarification shall provide that the sharing of such data shall be considered to be protected health information in accordance with the requirements of the regulations promulgated pursuant to such section #bfd7;c74 7,k7 ,education ,the ,secretary shall provide education to enrollees in prescription drug plans of ,,pdp sponsors and providers regarding the drug management program for at-risk beneficiaries described in this paragraph1 including education-- 7i7 provided through the improper payment outreach and education program described in section #ahgd;,a7h72 and 7ii7 through current education efforts 7such as ,state health insurance assistance programs described in subsection 7a77#a77;,a7 of section #aai of the ,medicare ,improvements for ,patients and ,providers ,act of #bjjh 7#db ,u4,s4,c4 #acie;b-#c note77 and materials directed toward such enrollees4 7,l7 ,,cms compliance review ,the ,secretary shall ensure that existing plan sponsor compliance reviews and audit processes include the drug management programs for at-risk beneficiaries under this paragraph1 including appeals processes under such programs4 4 7#b7 ,information for consumers ,section #ahfj;,d-#d7;a77#a77;,b7 of the ,social ,security ,act 7#db ,u4,s4,c4 #aciew-#ajd7;a77#a77;,b77 is amended by adding at the end the following3 7v7 ,the drug management program for at-risk beneficiaries under subsection 7c77#e74 4 7#c7 ,dual eligibles ,section #ahfj;,d-#a7;b77#c77;,d7 of the ,social ,security ,act 7#db ,u4,s4,c4 #aciew-#aja7;b77#c77;,d77 is amended by inserting 1 subject to such limits as the ,secretary may establish for individuals identified pursuant to section #ahfj;,d-#d7;c77#e7 after the ,secretary4 7b7 ,utilization management programs ,section #ahfj;,d-#d7;c7 of the ,social ,security ,act 7#db ,u4,s4,c4 #aciew-#ajd7;c771 as amended by subsection 7a77#a71 is amended-- 7#a7 in paragraph 7#a71 by inserting after subparagraph 7,d7 the following new subparagraph3 7,e7 ,a utilization management tool to prevent drug abuse 7as described in paragraph 7#e77;,a774 2 and 7#b7 by adding at the end the following new paragraph3 7#f7 ,utilization management tool to prevent drug abuse 7,a7 ,in general ,a tool described in this paragraph is any of the following3 7i7 ,a utilization tool designed to prevent the abuse of frequently abused drugs by individuals and to prevent the diversion of such drugs at pharmacies4 7ii7 ,retrospective utilization review to identify-- 7,i7 individuals that receive frequently abused drugs at a frequency or in amounts that are not clinically appropriate2 and 7,,ii7 providers of services or suppliers that may facilitate the abuse or diversion of frequently abused drugs by beneficiaries4 7iii7 ,consultation with the contractor described in subparagraph 7,b7 to verify if an individual enrolling in a prescription drug plan offered by a ,,pdp sponsor has been previously identified by another ,,pdp sponsor as an individual described in clause 7ii77,i74 7,b7 ,reporting ,a ,,pdp sponsor offering a prescription drug plan in a ,state shall submit to the ,secretary and the ,medicare drug integrity contractor with which the ,secretary has entered into a contract under section #ahic with respect to such ,state a report1 on a monthly basis1 containing information on-- 7i7 any provider of services or supplier described in subparagraph 7,a77ii77,,ii7 that is identified by such plan sponsor during the #cj-;day period before such report is submitted2 and 7ii7 the name and prescription records of individuals described in paragraph 7#e77;,c74 7,c7 ,,cms compliance review ,the ,secretary shall ensure that plan sponsor annual compliance reviews and program audits include a certification that utilization management tools under this paragraph are in compliance with the requirements for such tools4 4 7c7 ,treatment of certain complaints for purposes of quality or performance assessment ,section #ahfj;,d-#db of the ,social ,security ,act 7#db ,u4,s4,c4 #aciew-#aeb7 is amended by adding at the end the following new subsection3 7d7 ,treatment of certain complaints for purposes of quality or performance assessment ,in conducting a quality or performance assessment of a ,,pdp sponsor1 the ,secretary shall develop or utilize existing screening methods for reviewing and considering complaints that are received from enrollees in a prescription drug plan offered by such ,,pdp sponsor and that are complaints regarding the lack of access by the individual to prescription drugs due to a drug management program for at-risk beneficiaries4 4 7d7 ,sense of ,congress regarding use of technology tools ,to combat fraud ,it is the sense of ,congress that ,,ma organizations and ,,pdp sponsors should consider using e-prescribing and other health information technology tools to support combating fraud under ,,ma-,,pd plans and prescription drug plans under parts ,c and ,d of the ,medicare ,program4 7e7 ,,gao study and report 7#a7 ,study ,the ,comptroller ,general of the ,united ,states shall conduct a study on the implementation of the amendments made by this section1 including the effectiveness of the at-risk beneficiaries for prescription drug abuse drug management programs authorized by section #ahfj;,d-#d7;c77#e7 of the ,social ,security ,act 7#db ,u4,s4,c4 #aciew-#aj7;c77#e771 as added by subsection 7a77#a74 ,such study shall include an analysis of-- 7,a7 the impediments1 if any1 that impair the ability of individuals described in subparagraph 7,c7 of such section #ahfj;,d-#d7;c77#e7 to access clinically appropriate levels of prescription drugs2 7,b7 the effectiveness of the reasonable access protections under subparagraph 7,d77ii7 of such section #ahfj;,d-#d7;c77#e71 including the impact on beneficiary access and health2 7,c7 how best to define the term designated pharmacy1 including whether the definition of such term should include an entity that is comprised of a number of locations that are under common ownership and that electronically share a real-time1 online database and whether such a definition would help to protect and improve beneficiary access2 7,d7 the types of-- 7i7 individuals who1 in the implementation of such section1 are determined to be individuals described in such subparagraph2 and 7ii7 prescribers and pharmacies that are selected under subparagraph 7,d7 of such section2 7,e7 the extent of prescription drug abuse beyond ,controlled ,drug ,substances in ,schedule ,,cii in parts ,c and ,d of the ,medicare program2 and 7,f7 other areas determined appropriate by the ,comptroller ,general4 7#b7 ,report ,not later than ,july #a1 #bjai1 the ,comptroller ,general of the ,united ,states shall submit to the appropriate committees of jurisdiction of ,congress a report on the study conducted under paragraph 7#a71 together with recommendations for such legislation and administrative action as the ,comptroller ,general determines to be appropriate4 7f7 ,report by ,secretary 7#a7 ,in general ,not later than #ab months after the date of the enactment of this ,act1 the ,secretary of ,health and ,human ,services shall submit to the appropriate committees of jurisdiction of ,congress a report on ways to improve upon the appeals process for ,medicare beneficiaries with respect to prescription drug coverage under part ,d of title ,,xviii of the ,social ,security ,act4 ,such report shall include an analysis comparing appeals processes under parts ,c and ,d of such title ,,xviii4 7#b7 ,feedback ,in development of the report described in paragraph 7#a71 the ,secretary of ,health and ,human ,services shall solicit feedback on the current appeals process from stakeholders1 such as beneficiaries1 consumer advocates1 plan sponsors1 pharmacy benefit managers1 pharmacists1 providers1 independent review entity evaluators1 and pharmaceutical manufacturers4 7g7 ,effective date 7#a7 ,in general ,except as provided in subsection 7d77#b71 the amendments made by this section shall apply to prescription drug plans for plan years beginning on or after ,january #a1 #bjah4 7#b7 ,stakeholder meetings prior to effective date 7,a7 ,in general ,not later than ,january #a1 #bjag1 the ,secretary of ,health and ,human ,services shall convene stakeholders1 including individuals entitled to benefits under part ,a of title ,,xviii of the ,social ,security ,act or enrolled under part ,b of such title of such ,act1 advocacy groups representing such individuals1 clinicians1 plan sponsors1 pharmacists1 retail pharmacies1 entities delegated by plan sponsors1 and biopharmaceutical manufacturers for input regarding the topics described in subparagraph 7,b74 ,the input described in the preceding sentence shall be provided to the ,secretary in sufficient time in order for the ,secretary to take such input into account in promulgating the regulations pursuant to subparagraph 7,c74 7,b7 ,topics described ,the topics described in this subparagraph are the topics of-- 7i7 the impact on cost-sharing and ensuring accessibility to prescription drugs for enrollees in prescription drug plans of ,,pdp sponsors who are at-risk beneficiaries for prescription drug abuse 7as defined in paragraph 7#e77;,c7 of section #ahfj;,d-#d7;c7 of the ,social ,security ,act 7#db ,u4,s4,c4 #aciew-#aj7;c7772 7ii7 the use of an expedited appeals process under which such an enrollee may appeal an identification of such enrollee as an at-risk beneficiary for prescription drug abuse under such paragraph 7similar to the processes established under the ,medicare ,advantage program under part ,c of title ,,xviii of the ,social ,security ,act72 7iii7 the types of enrollees that should be treated as exempted individuals1 as described in clause 7ii7 of such paragraph2 7iv7 the manner in which terms and definitions in paragraph 7#e7 of such section #ahfj;,d-#d7;c7 should be applied1 such as the use of clinical appropriateness in determining whether an enrollee is an at-risk beneficiary for prescription drug abuse as defined in subparagraph 7,c7 of such paragraph 7#e72 7v7 the information to be included in the notices described in subparagraph 7,b7 of such section and the standardization of such notices2 7vi7 with respect to a ,,pdp sponsor that establishes a drug management program for at-risk beneficiaries under such paragraph 7#e71 the responsibilities of such ,,pdp sponsor with respect to the implementation of such program2 7vii7 notices for plan enrollees at the point of sale that would explain why an at-risk beneficiary has been prohibited from receiving a prescription at a location outside of the designated pharmacy2 7viii7 evidence-based prescribing guidelines for opiates2 and 7ix7 the sharing of claims data under parts ,a and ,b with ,,pdp sponsors4 7,c7 ,rulemaking ,the ,secretary of ,health and ,human ,services shall1 taking into account the input gathered pursuant to subparagraph 7,a7 and after providing notice and an opportunity to comment1 promulgate regulations to carry out the provisions of1 and amendments made by subsections 7a7 and 7b74 ,,viii ,transnational ,drug ,trafficking ,act #hja4 ,short title ,this title may be cited as the ,transnational ,drug ,trafficking ,act of #bjae4 #hjb4 ,possession1 manufacture or distribution for purposes of unlawful importations ,section #ajji of the ,controlled ,substances ,import and ,export ,act 7#ba ,u4,s4,c4 #iei7 is amended-- 7#a7 by redesignating subsections 7b7 and 7c7 as subsections 7c7 and 7d71 respectively2 and 7#b7 in subsection 7a71 by striking ,it shall and all that follows and inserting the following3 8,it shall be unlawful for any person to manufacture or distribute a controlled substance in schedule ,i or ,,ii or flunitrazepam or a listed chemical intending1 knowing1 or having reasonable cause to believe that such substance or chemical will be unlawfully imported into the ,united ,states or into waters within a distance of #ab miles of the coast of the ,united ,states4 7b7 ,it shall be unlawful for any person to manufacture or distribute a listed chemical-- 7#a7 intending or knowing that the listed chemical will be used to manufacture a controlled substance2 and 7#b7 intending1 knowing1 or having reasonable cause to believe that the controlled substance will be unlawfully imported into the ,united ,states4 4 #hjc4 ,trafficking in counterfeit goods or services ,chapter #aac of title #ah1 ,united ,states ,code1 is amended-- 7#a7 in section #bcah7;b77#b71 by striking section #bcbj7;e7 and inserting section #bcbj7;f72 and 7#b7 in section #bcbj-- 7,a7 in subsection 7a71 by striking paragraph 7#d7 and inserting the following3 7#d7 traffics in a drug and knowingly uses a counterfeit mark on or in connection with such drug1 2 7,b7 in subsection 7b77#c71 in the matter preceding subparagraph 7,a71 by striking counterfeit drug and inserting drug that uses a counterfeit mark on or in connection with the drug2 and 7,c7 in subsection 7f71 by striking paragraph 7#f7 and inserting the following3 7#f7 the term drug means a drug1 as defined in section #bja of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cba74 4 ,passed the ,senate ,march #aj1 #bjaf4,secretary